<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">90316</article-id><article-id pub-id-type="doi">10.7554/eLife.90316</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.90316.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Kejia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1089-6782</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Eldin</surname><given-names>Patrick</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3678-1043</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ciesla</surname><given-names>Jessica H</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Briant</surname><given-names>Laurence</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1995-3501</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lentini</surname><given-names>Jenna M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ramos</surname><given-names>Jillian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cobb</surname><given-names>Justin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Munger</surname><given-names>Joshua</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fu</surname><given-names>Dragony</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8725-8658</contrib-id><email>DFU4@ur.rochester.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/022kthw22</institution-id><institution>Department of Biology, Center for RNA Biology, University of Rochester</institution></institution-wrap><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036eg1q44</institution-id><institution>Institut de Recherche en Infectiologie de Montpellier (IRIM), CNRS, UMR 9004, Université de Montpellier</institution></institution-wrap><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00trqv719</institution-id><institution>Department of Biochemistry and Biophysics, University of Rochester Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Gupta</surname><given-names>Yogesh K</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02f6dcw23</institution-id><institution>The University of Texas Health Science Center at San Antonio</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01swzsf04</institution-id><institution>University of Geneva</institution></institution-wrap><country>Switzerland</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>05</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP90316</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-08"><day>08</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-07-20"><day>20</day><month>07</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.10.527147"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-13"><day>13</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90316.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-19"><day>19</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90316.2"/></event></pub-history><permissions><copyright-statement>© 2023, Zhang et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Zhang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-90316-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-90316-figures-v2.pdf"/><related-article related-article-type="article-reference" ext-link-type="doi" xlink:href="10.7554/eLife.91168" id="ra1"/><abstract><p>Nonstructural protein 5 (Nsp5) is the main protease of SARS-CoV-2 that cleaves viral polyproteins into individual polypeptides necessary for viral replication. Here, we show that Nsp5 binds and cleaves human tRNA methyltransferase 1 (TRMT1), a host enzyme required for a prevalent post-transcriptional modification in tRNAs. Human cells infected with SARS-CoV-2 exhibit a decrease in TRMT1 protein levels and TRMT1-catalyzed tRNA modifications, consistent with TRMT1 cleavage and inactivation by Nsp5. Nsp5 cleaves TRMT1 at a specific position that matches the consensus sequence of SARS-CoV-2 polyprotein cleavage sites, and a single mutation within the sequence inhibits Nsp5-dependent proteolysis of TRMT1. The TRMT1 cleavage fragments exhibit altered RNA binding activity and are unable to rescue tRNA modification in TRMT1-deficient human cells. Compared to wild-type human cells, TRMT1-deficient human cells infected with SARS-CoV-2 exhibit reduced levels of intracellular viral RNA. These findings provide evidence that Nsp5-dependent cleavage of TRMT1 and perturbation of tRNA modification patterns contribute to the cellular pathogenesis of SARS-CoV-2 infection.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>The virus responsible for COVID-19 infections is known as SARS-CoV-2. Like all viruses, SARS-CoV-2 carries instructions to make proteins and other molecules that play essential roles in enabling the virus to multiply and spread. Viruses are unable to make these molecules themselves, so they infect cells and trick them into making the molecules and assembling new virus particles on their behalf instead.</p><p>When SARS-CoV2 infects cells, the host cells are reprogrammed to make chains containing several virus proteins that need to be severed from each other by a virus enzyme, known as Nsp5, to enable the proteins to work properly. Previous studies suggested that Nsp5 may also interact with a human protein known as TRMT1, which helps with the production of new proteins in cells. However, it was not clear how Nsp5 may bind to TRMT1 or how this interaction may affect the host cell.</p><p>Zhang et al. used biochemical and molecular techniques in human cells to study how Nsp5 interacts with TRMT1. The experiments found that the virus enzyme cuts TRMT1 into fragments that are inactive and are subsequently destroyed by the cells. Moreover, Nsp5 cuts TRMT1 at exactly the same position corresponding to the cleavage sites of the viral proteins. Mutation of the sequence in TRMT1 renders Nsp5 ineffective at cutting the protein.</p><p>SARS-CoV-2 infection caused TRMT1 levels to decrease inside the cells, in turn, leading to a drop in TRMT1 activity. The virus multiplied less in cells that were unable to produce TRMT1 compared to normal human cells, suggesting that the virus benefits from TRMT1 early during infection, before inactivating it at a later point.</p><p>These findings suggest that one way SARS-CoV-2 causes disease is by decreasing the levels of a human protein that regulates protein production. In the future, the work of Zhang et al. may provide new markers for detecting infections of SARS-CoV-2 and other similar viruses and guide efforts to make more effective therapies against them.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV-2</kwd><kwd>coronavirus</kwd><kwd>tRNA</kwd><kwd>TRMT1</kwd><kwd>Nsp5</kwd><kwd>main protease</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>2033354</award-id><principal-award-recipient><name><surname>Fu</surname><given-names>Dragony</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM143145</award-id><principal-award-recipient><name><surname>Fu</surname><given-names>Dragony</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM068411</award-id><principal-award-recipient><name><surname>Ciesla</surname><given-names>Jessica H</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI1049815</award-id><principal-award-recipient><name><surname>Ciesla</surname><given-names>Jessica H</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI127370</award-id><principal-award-recipient><name><surname>Munger</surname><given-names>Joshua</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI50698</award-id><principal-award-recipient><name><surname>Munger</surname><given-names>Joshua</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100021565</institution-id><institution>Montpellier Université d'Excellence</institution></institution-wrap></funding-source><award-id>CoVIMOD FRS13</award-id><principal-award-recipient><name><surname>Eldin</surname><given-names>Patrick</given-names></name><name><surname>Briant</surname><given-names>Laurence</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>SARS-CoV-2 infection reduces the intracellular levels of a human tRNA modification enzyme and alters host tRNA modification profiles.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, single-stranded RNA virus that is the causative agent of the COVID-19 pandemic (<xref ref-type="bibr" rid="bib31">Lamers and Haagmans, 2022</xref>; <xref ref-type="bibr" rid="bib42">Merad et al., 2022</xref>). SARS-CoV-2 is a member of the Betacoronavirus genus of the Coronaviridae family, which includes the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV) (reviewed in <xref ref-type="bibr" rid="bib20">Hartenian et al., 2020</xref>). SARS-CoV-2 primarily targets the human respiratory tract and lungs, which can clinically manifest as an acute respiratory distress syndrome. Once delivered into the host cell, the incoming positive-strand viral RNA genome is first translated by host ribosomes into two overlapping polyproteins, pp1a and pp1ab. Viral polyproteins are then proteolytically processed into 16 mature nonstructural proteins (Nsps) involved in the assembly of the viral replication-transcription complex (reviewed in <xref ref-type="bibr" rid="bib77">V’kovski et al., 2021</xref>). The Nsps also participate in disrupting host cellular processes and pathways to escape immune recognition and facilitate viral propagation (reviewed in <xref ref-type="bibr" rid="bib45">Minkoff and tenOever, 2023</xref>; <xref ref-type="bibr" rid="bib69">Suryawanshi et al., 2021</xref>).</p><p>The maturation step to release the individual Nsp polypeptides is executed by two viral-encoded proteases: Nsp5 (also known as Main Protease, M<sup>Pro</sup>/3C-like protease) and Nsp3 (also known as Papain-Like Protease, PL<sup>Pro</sup>) (<xref ref-type="bibr" rid="bib49">Narayanan et al., 2022</xref>). Nsp3 is contained within pp1a and releases itself from the polyprotein through self-cleavage. Nsp3 also cleaves pp1a at multiple sites to release Nsp1 through Nsp4 (<xref ref-type="bibr" rid="bib80">Yan and Wu, 2021</xref>). The Nsp5 main protease processes pp1b at eleven sites to release itself and Nsp4 to Nsp16 (<xref ref-type="bibr" rid="bib8">Chen et al., 2021</xref>). Besides cleaving viral substrates, Nsp3 and Nsp5 have also been found to cleave endogenous host proteins linked to the immune response and cell survival (<xref ref-type="bibr" rid="bib40">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib43">Meyer et al., 2021</xref>; <xref ref-type="bibr" rid="bib44">Meyers et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Moustaqil et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Wenzel et al., 2021</xref>; <xref ref-type="bibr" rid="bib84">Zhang et al., 2021b</xref>). Nsp3 and Nsp5 are essential for viral replication and represent well-characterized drug targets among coronaviruses. Notably, the active component of the antiviral drug Paxlovid is nirmatrelvir, a reversible covalent inhibitor of the Nsp5 main protease (<xref ref-type="bibr" rid="bib53">Owen et al., 2021</xref>). By inhibiting Nsp5 proteolytic activity, Paxlovid reduces viral replication and disease severity in patients with COVID-19.</p><p>Purification of individual SARS-CoV-2 proteins from human cells have identified a potential interaction between a catalytic-inactive version of Nsp5 with human TRMT1 (<xref ref-type="bibr" rid="bib17">Gordon et al., 2020a</xref>). A cross-coronavirus investigation from the same group has extended this observation by finding that TRMT1 interacts with a catalytic-inactive version of Nsp5 encoded by SARS-CoV-1, which is 98.7% similar to SARS-CoV-2 (<xref ref-type="bibr" rid="bib18">Gordon et al., 2020b</xref>). Interestingly, the same study found no detectable interaction between TRMT1 and Nsp5 encoded by MERS-CoV, which has 66.8% similarity with SARS-CoV-2. TRMT1 was also identified as a potential interactor with catalytic-inactive Nsp5 using proximity-dependent biotinylation (<xref ref-type="bibr" rid="bib64">Samavarchi-Tehrani et al., 2020</xref>).</p><p>TRMT1 is a tRNA modification enzyme that catalyzes the formation of dimethylguanosine (m2,2G) at position 26 in more than half of all human tRNAs (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Jonkhout et al., 2021</xref>). The m2,2G modification is located at a key structural position in tRNAs and is hypothesized to play a role in proper tRNA folding (<xref ref-type="bibr" rid="bib54">Pallan et al., 2008</xref>; <xref ref-type="bibr" rid="bib68">Steinberg and Cedergren, 1995</xref>). TRMT1-deficient human cells exhibit perturbations in global protein synthesis and decreased proliferation (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). Moreover, loss-of-function variants in the <italic>TRMT1</italic> gene are the cause of certain types of intellectual disability disorders in humans (<xref ref-type="bibr" rid="bib3">Blaesius et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Najmabadi et al., 2011</xref>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2020</xref>). Thus, changes in TRMT1 activity can impact protein synthesis leading to downstream cellular and biological effects.</p><p>The life cycle of many viruses has been linked to host tRNA biology (reviewed in <xref ref-type="bibr" rid="bib14">Dremel et al., 2023</xref>; <xref ref-type="bibr" rid="bib52">Nunes et al., 2020</xref>). In one well-known example, retroviruses such as HIV use cellular tRNAs as primers for reverse transcription and other viral functions (reviewed in <xref ref-type="bibr" rid="bib23">Jin and Musier-Forsyth, 2019</xref>). DNA and RNA viruses can also impact tRNA synthesis, processing, and charging to modulate infection and pathogenesis (<xref ref-type="bibr" rid="bib13">Dremel et al., 2022</xref>; <xref ref-type="bibr" rid="bib50">Netzer et al., 2009</xref>; <xref ref-type="bibr" rid="bib72">Tucker et al., 2020</xref>). In a recent study, Chikungunya RNA virus infection has been shown to increase the expression of a human tRNA modification enzyme and alter tRNA modification patterns to favor viral protein expression (<xref ref-type="bibr" rid="bib27">Jungfleisch et al., 2022</xref>). Interestingly, SARS-CoV-2 viral particles exhibit an enrichment of specific host tRNAs with distinct modification profiles (<xref ref-type="bibr" rid="bib56">Peña et al., 2022</xref>). Moreover, analysis of RNA extracted from human nose swabs have identified tRNA profiles and modification signatures associated with mild versus severe COVID-19 (<xref ref-type="bibr" rid="bib29">Katanski et al., 2022</xref>). The change in tRNA modification profiles could represent another mechanism employed by SARS-CoV-2 to take over translation in addition to previously described strategies (<xref ref-type="bibr" rid="bib15">Finkel et al., 2021</xref>).</p><p>The putative interaction between Nsp5 and TRMT1 indicates that SARS-CoV-2 infection could affect the function of TRMT1 with consequent effects on tRNA modification levels. However, the association between Nsp5 and TRMT1 has not been validated nor characterized. Here, we find that TRMT1 is an endogenous cleavage target of Nsp5 resulting in methyltransferase inactive cleavage products. Moreover, we find that SARS-CoV-2 infection correlates with decreased TRMT1 levels and a reduction in m2,2G-modified tRNAs. In addition, we provide evidence that TRMT1 expression is required for efficient SARS-CoV-2 replication in human cells. These studies uncover TRMT1 as a novel proteolytic cleavage target of Nsp5 during SARS-CoV-2 infection and suggest possible pathological mechanisms associated with perturbations in TRMT1-catalyzed tRNA modifications.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SARS-CoV-2 infection reduces cellular levels of TRMT1 and TRMT1-catalyzed tRNA modifications</title><p>To test the effects of SARS-CoV-2 infection on TRMT1 and tRNA modifications, we used an MRC-5 human lung fibroblast cell line expressing the ACE2 receptor that is permissive for SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib61">Raymonda et al., 2022</xref>; <xref ref-type="bibr" rid="bib73">Uemura et al., 2021a</xref>; <xref ref-type="bibr" rid="bib74">Uemura et al., 2021b</xref>). MRC-5 cells were mock-infected or infected with SARS-CoV-2 followed by harvesting at 24- and 48 hr post-infection for sample preparation. We chose the 24- and 48 hr time points since MRC5-ACE2 cells exhibit elevated accumulation of viral RNA at these time points without extreme cell death that occurs at subsequent time points (<xref ref-type="bibr" rid="bib61">Raymonda et al., 2022</xref>). Immunoblotting for the SARS-CoV-2 nucleocapsid (N) protein confirmed the infection and expression of viral proteins in MRC-5 cells compared to mock-infected cells (<xref ref-type="fig" rid="fig1">Figure 1A and N</xref> protein, compare lanes 1 and 2 to lanes 3 and 4). To probe for TRMT1, we used an antibody that detects the major TRMT1 isoform of ~72 kDa as well as a non-specific band at ~65 kDa in human cell lysates (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Perez et al., 2022</xref>). Using this antibody, we also detected the 72 kDa TRMT1 isoform as well as the non-specific 65 kDa band in MRC-5 cell lysates (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, circle denotes TRMT1, asterisk denotes non-specific band). In multiple independent replicates, MRC-5 cells infected with SARS-CoV-2 exhibited a ~30% reduction in TRMT1 levels at 24- and 48 hr post-infection compared to mock-infected cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). These results provide evidence that SARS-CoV-2 infection reduces cellular levels of TRMT1.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Human cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a reduction in tRNA methyltransferase 1 (TRMT1) levels and perturbations in tRNA modification patterns.</title><p>(<bold>A</bold>) Immunoblot analysis of lysates prepared from MRC-5-ACE2 human cells that were mock-infected or infected with SARS-CoV-2 at multiplicity of infection (MOI) of 5 for 24 or 48 hr. The immunoblot was probed with anti-TRMT1, actin, or SARS-CoV-2 nucleocapsid (N) antibodies. Circle represents endogenous full-length TRMT1. Asterisk (*) denotes a non-specific band. Size markers are noted in kiloDalton. (<bold>B</bold>) Quantification of TRMT1 signal intensity normalized to actin in the mock or SARS-CoV-2-infected cell lines. TRMT1 protein levels are expressed relative to mock-infected samples for each time point. (<bold>C</bold>) m2,2G levels in small RNAs isolated from MRC5 cells that were either mock-infected or infected with SARS-CoV-2 at MOI of 5 for 24 or 48 hr. m2,2G levels were normalized to A, C, G, and U. Samples were measured in biological replicates. Statistical significance for (<bold>B</bold>) and (<bold>C</bold>) was determined by two-way ANOVA with multiple comparisons test. ***p&lt;0.001; ****p&lt;0.0001; ns, non-significant. (<bold>D</bold>) Levels of the indicated RNA modifications in small RNAs isolated from MRC5 cells that were either mock-infected or infected with SARS-CoV-2 for 24 or 48 hr. RNA modification levels were normalized to A, C, G, and U. Y-axis represents the log2 fold change in the levels of the indicated tRNA modification between SARS-CoV-2 infected versus mock-infected MRC5 cells. The experiment in (<bold>C</bold>) was repeated as an independent biological replicate in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>LC-MS measurements of RNA modifications.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>LC-MS analysis of dimethylguanosine (m2,2G) levels in small RNAs isolated from MRC5 cells that were either mock-infected or infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at multiplicity of infection (MOI) of 5 for 24 or 48 hr.</title><p>m2,2G levels were normalized to guanosine. Samples were measured in biological replicates. Statistical significance was determined by two-way ANOVA with multiple comparisons test. *p&lt;0.05; ns, non-significant.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>LC-MS measurements of RNA modifications.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-90316-fig1-figsupp1-data1-v2.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig1-figsupp1-v2.tif"/></fig></fig-group><p>We next measured the levels of TRMT1-catalyzed m2,2G modifications in cellular RNA using quantitative mass spectrometry. While m2,2G levels did not exhibit a significant change between mock-infected and SARS-CoV-2-infected cells at 24 hr post-infection, m2,2G levels were decreased by ~15% at 48 hr post-infection in multiple biological replicates (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The decrease in m2,2G levels after SARS-CoV-2 infection was also reproduced in an independent experiment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In addition to m2,2G, more than half of all tested RNA modifications exhibited a decrease in SARS-CoV-2-infected cells compared to mock-infected cells at 24 hr post-infection (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). At 48 hr post-infection with SARS-CoV-2, most of the tested RNA modifications exhibited a decrease in levels compared to mock-infected cells. The RNA modifications that decrease upon viral infection include modifications that are known to be present in multiple types of RNA, including tRNA, rRNA, and mRNA. Thus, SARS-CoV-2 infection of human MRC-5 lung fibroblast cells alters the steady-state levels of multiple RNA modifications, including the m2,2G modification catalyzed by TRMT1.</p></sec><sec id="s2-2"><title>Nsp5 interacts with TRMT1</title><p>Examination of the primary structure of human TRMT1 revealed an eight amino acid residue sequence between the methyltransferase domain and zinc-finger motif matching the consensus sequence of Nsp5 cleavage sites in SARS-CoV-2 polyproteins (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). The putative cleavage site in TRMT1 includes a glutamine (Q) residue conserved at the fourth position that is found in all Nsp5 cleavage sites of SARS-CoV-2 polyproteins (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Based upon a predicted tertiary structure of TRMT1 using Alpha Fold (<xref ref-type="bibr" rid="bib26">Jumper et al., 2021</xref>; <xref ref-type="bibr" rid="bib76">Varadi et al., 2022</xref>), this putative Nsp5 cleavage site is expected to lie in an unstructured linker region exposed on the surface of TRMT1 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein 5 (Nsp5) binds tRNA methyltransferase 1 (TRMT1) in human cells.</title><p>(<bold>A</bold>) Schematic of human TRMT1 primary structure with predicted Nsp5 cleavage site. Mitochondrial targeting signal (MTS), methyltransferase (MT) domain, and zinc finger motif are denoted. (<bold>B</bold>) Consensus sequence logo of cleavage sites in SARS-CoV-2 polyproteins. (<bold>C</bold>) Alpha-fold predicted structure of human TRMT1 with putative Nsp5 cleavage site denoted in magenta and arrowhead. (<bold>D</bold>) Immunoblot of input and strep-tactin purifications from human cells expressing empty vector, wild-type (WT) Nsp5, or Nsp5-C145A fused to the Strep-tag without or with co-expression with TRMT1-FLAG. The immunoblot was probed with anti-Strep, FLAG, and actin antibodies. Square represents TRMT1-FLAG, circle represents endogenous TRMT1. Size markers are noted to the left in kiloDalton. The experiment in (<bold>D</bold>) was repeated as an independent biological replicate in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Immunoblot of input and strep-tactin purifications from human cells expressing empty vector, wild-type (WT) nonstructural protein 5 (Nsp5), or Nsp5-C145A fused to the Strep-tag without or with co-expression with tRNA methyltransferase 1 (TRMT1)-FLAG.</title><p>The immunoblot was probed with anti-TRMT1, Strep, or actin antibodies. Circle represents endogenous TRMT1.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To investigate a potential interaction between Nsp5 and TRMT1, we used human 293T cells due to their high transfection efficiency. We transfected human 293T cells with plasmids expressing wild-type (WT) Nsp5 from SARS-CoV-2 or Nsp5-C145A. The Nsp5-C145A mutant contains an alanine substitution of the catalytic cysteine residue in the active site of Nsp5 and is proteolytically inactive (<xref ref-type="bibr" rid="bib33">Lee et al., 2020</xref>). The Nsp5 proteins were expressed as fusion proteins with the Twin-Strep purification tag (<xref ref-type="bibr" rid="bib66">Schmidt et al., 2013</xref>). We also tested the interaction between Strep-tagged Nsp5 or Nsp5-C145A with TRMT1 by co-expression with TRMT1 fused with a carboxyl-terminal FLAG tag. TRMT1 was tagged at the carboxy-terminus to prevent interference with the amino-terminal mitochondrial targeting signal (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). The Strep-tagged Nsp5 or Nsp5-C145A mutants were affinity purified from cell lysates on strep-tactin resin, eluted with biotin, and purified proteins detected by immunoblotting. Probing of input lysates and purified samples with anti-Strep antibodies confirmed the expression and recovery of WT-Nsp5 and Nsp5-C145A (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, Strep). Nsp5-C145A protein accumulated at higher levels compared to WT-Nsp5 due to the absence of self-cleavage by Nsp5-C145A and the known toxicity of expressing WT-Nsp5 in mammalian cells (<xref ref-type="bibr" rid="bib63">Resnick et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Wenzel et al., 2021</xref>).</p><p>To probe for TRMT1, we used the antibody described above that detects endogenous full-length TRMT1 of 72 kDa (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, input lanes 1–3, circle denotes endogenous TRMT1). The antibody also detected the overexpressed TRMT1-FLAG protein (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, lanes 4–6, square denotes TRMT1-FLAG). Only background levels of endogenous TRMT1 or TRMT1-FLAG were detected in the vector or WT-Nsp5 purifications (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, TRMT1, low or high exposure, lanes 7, 8, 10, and 11). In contrast, endogenous TRMT1 was enriched in the purification with Nsp5-C145A (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, TRMT1 high exposure, lane 9). TRMT1-FLAG was also detected specifically in the Nsp5-C145A purification compared to the control or Nsp5 purifications (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, compare lanes 10 and 11 to lane 12). The association between TRMT1 and Nsp5-C145A was reproduced in an independent purification (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). These results provide evidence that Nsp5 can interact with TRMT1 when Nsp5 is in the catalytic-inactive form.</p></sec><sec id="s2-3"><title>Nsp5 cleaves TRMT1 in a site-specific manner</title><p>The interaction of TRMT1 with Nsp5-C145A along with cleavage site prediction suggests that TRMT1 could be a proteolysis substrate of Nsp5. To test this hypothesis, we monitored for TRMT1 cleavage in 293T human cells expressing Strep-tagged Nsp5 or GFP as a control. Cleavage after amino acid residue 530 of TRMT1 is predicted to result in an N-terminal fragment of 58 kDa and a C-terminal fragment of 14 kDa. To probe for the N-terminal TRMT1 fragment, we used the antibody described above which targets residues 201–229 of TRMT1. Using this antibody, we detected full-length TRMT1 and the ~65 kDa non-specific band in lysates from 293T cells expressing Strep-GFP (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, TRMT1, lanes 1–3, circle and asterisk, respectively). No detectable change in the levels of full-length TRMT1 was observed in human cells expressing Nsp5 or Nsp5-C145A (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, TRMT1, quantified in 3B). However, lysates prepared from human cells expressing Nsp5 exhibited an additional band migrating below the non-specific band that matches the predicted size of the N-terminal TRMT1 fragment (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, TRMT1, lanes 4–6, arrow). The putative N-terminal TRMT1 fragment was detectable at 24 hr post-transfection with the Nsp5-expression plasmid, increased at 48 hr, and remained detectable at 72 hr post-transfection (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). In contrast, the N-terminal TRMT1 fragment was not detected above the background signal in human cells expressing the proteolytically inactive Nsp5-C145A mutant (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, TRMT1, lanes 7–9, quantified in 3 C).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Nonstructural protein 5 (Nsp5) expression induces cleavage of tRNA methyltransferase 1 (TRMT1) in human cells.</title><p>(<bold>A</bold>) Immunoblot of lysates prepared from human 293T cells expressing GFP, Nsp5 or Nsp5-C145A. The immunoblot was probed with anti-TRMT1, Strep, or actin antibodies. Hours post represents the time post-transfection. Circle represents endogenous TRMT1. Arrow represents the N-terminal (N)-TRMT1 cleavage fragment. Asterisk (*) denotes a non-specific band. Size markers to the left in kiloDalton. (<bold>B, C</bold>) Quantification of endogenous TRMT1 or N-terminal (N)-TRMT1 cleavage product in transfected cells. TRMT1 and N-TRMT1 signal was normalized to actin. (<bold>D</bold>) Immunoblot of lysates prepared from wild-type or TRMT1-knockout (KO) human cell lines expressing Nsp5. Experiments in (<bold>A</bold>) and (<bold>D</bold>) were repeated three times in biological replicates (see source data).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig3-v2.tif"/></fig><p>We validated the specificity of our results by using a human 293T TRMT1‐knockout (KO) cell line that is deficient in TRMT1 expression (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2020</xref>). In this case, neither full-length TRMT1 nor the TRMT1 cleavage fragment were detected in a TRMT1-deficient human cell line expressing Nsp5 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, compare lanes 1 through 3 to lanes 4 through 6). This result provides additional confirmation that the N-terminal TRMT1 fragment arises from the cleavage of endogenous TRMT1 by Nsp5.</p><p>We also attempted to detect the C-terminal TRMT1 cleavage fragment in human cells expressing Nsp5 using an antibody targeting residues 609–659 of TRMT1 (<xref ref-type="bibr" rid="bib85">Zhang et al., 2021c</xref>). This anti-TRMT1 antibody detects the full-length 72 kDa TRMT1 isoform that is absent in TRMT1-KO cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>, lanes 1 and 2). However, no additional band matching the expected size of the C-terminal fragment was detected in human cells expressing Nsp5 compared to cells expressing GFP or Nsp5-C145A (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>, lanes 3 through 6). This could be due to degradation of the C-terminal TRMT1 fragment and/or low sensitivity of the antibody.</p><p>To increase the sensitivity for detecting the C-terminal TRMT1 fragment, we co-transfected Nsp5 expression plasmids along with a plasmid encoding TRMT1 fused to a FLAG tag at the C-terminus. Confirming the results above with endogenous TRMT1, the N-terminal TRMT1 cleavage product was detected in the lysate of human cells overexpressing TRMT1-FLAG and Nsp5 but not with vector or Nsp5-C145A (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, TRMT1, compare lanes 1 and 3 to lane 2). In addition, using an antibody against the FLAG tag, we could detect a ~20 kDa product matching the expected molecular weight of a FLAG-tagged C-terminal TRMT1 cleavage product in the lysate of human cells expressing Nsp5 but not vector alone or Nsp5-C145A (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, FLAG, arrowhead). To confirm that the 20 kDa band detected with the anti-FLAG antibody was the C-terminal portion of TRMT1, we probed the cell lysates with the anti-TRMT1 antibody targeting residues 609–659 noted above. Using this antibody, we detected the same ~20 kDa band in the lysate of human cells expressing Nsp5 but not vector alone or Nsp5-C145A (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>, lanes 1–3). These data provide evidence that SARS-CoV-2 Nsp5 cleaves at the predicted cleavage site in TRMT1 leading to N- and C-terminal fragments in human cells.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Sequence-dependent cleavage of tRNA methyltransferase 1 (TRMT1) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein 5 (Nsp5).</title><p>(<bold>A</bold>) Immunoblot of lysates from human cells expressing empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep without or with co-expression with TRMT1-FLAG. The immunoblot was probed with anti-Strep, FLAG, and actin antibodies. Square represents TRMT1-FLAG, Asterisk (*) denotes a non-specific band, arrow represents N-terminal TRMT1 cleavage product and arrowhead indicates the C-terminal TRMT1 cleavage product. (<bold>B</bold>) Schematic of human TRMT1 with predicted Nsp5 cleavage site and Q530N mutation. (<bold>C</bold>) Immunoblot of lysates from human cells expressing empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep without or with co-expression with TRMT1-FLAG or TRMT1-FLAG Q530N. Experiments in (<bold>A</bold>) and (<bold>C</bold>) were repeated three times as biological replicates with comparable results (see source data).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Detection of the C-terminal tRNA methyltransferase 1 (TRMT1) fragment produced by nonstructural protein 5 (Nsp5)-dependent cleavage in human cells.</title><p>(<bold>A</bold>) Immunoblot of lysates from the indicated wild-type (WT) or TRMT1-knockout (K)O human 293T cells that were untransfected (-) (lanes 1 and 2) or transfected with empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep expression plasmids (lanes 3 through 5). The blot was probed with an antibody detecting residues 609–659 of TRMT1. Circle represents endogenous TRMT1. (<bold>B</bold>) Immunoblot of lysates from human cells that were transfected with TRMT1-FLAG or TRMT1-FLAG Q530N expression plasmids along with empty vector, wild-type (WT) Nsp5-Strep, or Nsp5-C145A-Strep expression plasmids. The blot was probed with an antibody detecting residues 609–659 of TRMT1. Circle represents endogenous TRMT1, square represents TRMT1-FLAG, and arrowhead indicates the C-terminal TRMT1 cleavage product. Asterisks (*) denote bands that are still detectable in the TRMT1-KO cell line. The band at ~35 kDa in lanes 3 and 6 of (<bold>B</bold>) represents non-specific detection of the Nsp5-C145A variant that exhibits extremely high levels of expression since it cannot self-cleave.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig4-figsupp1-v2.tif"/></fig></fig-group><p>All Nsp5 cleavage sites in SARS-CoV-1 and SARS-CoV-2 polyproteins contain a glutamine residue at position four (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="bibr" rid="bib19">Grum-Tokars et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Jin et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Lee et al., 2022</xref>). Mutation of the glutamine to asparagine is sufficient to abolish recognition and cleavage by Nsp5 from SARS-CoV-1 or SARS-CoV-2 (<xref ref-type="bibr" rid="bib21">Heilmann et al., 2022</xref>; <xref ref-type="bibr" rid="bib47">Muramatsu et al., 2013</xref>). Thus, we tested if TRMT1 exhibited the same requirements for cleavage by Nsp5 by generating an expression construct for TRMT1-FLAG in which residue Q530 of the predicted Nsp5 cleavage site was mutated to asparagine (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, Q530N). Further confirming our results above, expression of TRMT1-FLAG with WT-Nsp5 but not GFP or Nsp5-C145A led to the accumulation of N- and C-terminal TRMT1 cleavage fragments (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, TRMT1 and FLAG, lanes 4–6, arrow and arrowhead, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). In contrast to wild-type TRMT1, the appearance of the N- or C-terminal TRMT1 cleavage fragments was barely detectable when the TRMT1-Q530N mutant was co-expressed with Nsp5 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, lane 8, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Altogether, these results demonstrate that TRMT1 can be recognized and cleaved by Nsp5 in human cells with cleavage requiring a sequence that matches Nsp5 cleavage sites in SARS-CoV-2 polyproteins.</p></sec><sec id="s2-4"><title>Functional properties of TRMT1 fragments resulting from Nsp5 cleavage</title><p>Cleavage of TRMT1 after residue Q530 will result in an N-terminal fragment encompassing the methyltransferase domain and a C-terminal TRMT1 fragment containing a zinc finger motif that mediates tRNA interaction (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2020</xref>). Thus, we tested the functional properties of the predicted TRMT1 cleavage fragments compared to full-length TRMT1. First, we tested the interaction between the TRMT1 cleavage fragments and RNA. We have previously shown that TRMT1 exhibits a stable interaction with rRNAs and substrate tRNAs that are targets for m2,2G modification (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2020</xref>). Based upon this interaction, we expressed full-length TRMT1, the TRMT1-Q530N mutant, or the TRMT1 fragments as FLAG-tagged fusion proteins in 293T human cells followed by affinity purification and analysis of copurifying RNAs (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Immunoblotting confirmed the expression and purification of each TRMT1 variant on antiFLAG resin (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). As expected, the purification of full-length TRMT1 resulted in the enrichment of rRNA and tRNAs compared to the control purification from vector-transfected cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, compare lane 6 to lane 7). The Q530N variant of TRMT1 also exhibited comparable binding of tRNAs as full-length TRMT1 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, lane 10). In contrast, no detectable enrichment of rRNA or tRNA was detected for the N-terminal TRMT1 fragment (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, lane 8). Interestingly, the TRMT1 C-terminal fragment exhibited similar levels of tRNA binding as full-length TRMT1 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, compare lanes 7–9). Thus, the N-terminal TRMT1 cleavage fragment appears to be insufficient for binding tRNA while the C-terminal fragment containing the Zn-finger motif is sufficient for binding to tRNAs.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>N- and C-terminal tRNA methyltransferase 1 (TRMT1) cleavage fragments exhibit alterations in RNA binding and tRNA modification activity.</title><p>(<bold>A</bold>) Schematic of wild-type TRMT1 and predicted TRMT1 fragments resulting from nonstructural protein 5 (Nsp5) cleavage at Q530N. (<bold>B</bold>) Immunoblot analysis of anti-FLAG purifications from human cells expressing vector control, full-length TRMT1, or TRMT1 cleavage fragments fused to the FLAG tag. The immunoblot was probed with anti-FLAG and anti-actin antibodies. (<bold>C</bold>) Nucleic acid stain of RNAs extracted from the indicated input or purified samples after denaturing PAGE. The migration pattern of 5.8 S rRNA (~150 nt), 5 S rRNA (~120 nt), and tRNAs (~70–80 nt) are denoted. (<bold>D</bold>) Immunoblot of TRMT1 expression in either control-wild-type (WT) or TRMT1-knockout (KO) human 293T cell lines. (<bold>E, F</bold>) Representative gel of primer extension assays to monitor the presence of dimethylguanosine (m2,2G) in tRNA-Met-CAU or mt-tRNA-Ile-GAU from the cell lines transfected with the indicated TRMT1 constructs. D, dihydrouridine; m1G, 1-methylguanosine; &gt;, labeled oligonucleotide used for primer extension. Protein-RNA purification was repeated with comparable results (see source data for repeat).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Confocal microscopy images of 293T cells transiently transfected with constructs expressing tRNA methyltransferase 1 (TRMT1) or TRMT1 fragments fused with green fluorescent protein (GFP).</title><p>Mitochondria were identified using mitochondrion-targeted red fluorescent protein (Mito-RFP) and nuclear DNA was stained with Hoechst. Overlap of red mitochondria and green GFP signal is displayed in the Merge panels.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw uncropped microscopy images for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig5-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig5-figsupp1-v2.tif"/></fig></fig-group><p>To further dissect the functionality of the TRMT1 cleavage fragments, we next used the TRMT1‐KO human cell line described above. This TRMT1-KO cell line is deficient in TRMT1 and lacks m2,2G modifications in all tested tRNAs containing G at position 26 (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2020</xref>). Using transient transfection, we expressed full-length TRMT1 or the TRMT1 variants in either the control wild-type (WT) or TRMT1-KO cell lines (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). We then assessed for rescue of m2,2G formation in nuclear-encoded tRNA‐Met‐CAU or mitochondrial-encoded (mt)-tRNA-Ile-UAU using a reverse transcriptase (RT)-based primer extension assay. Based upon this assay, vector‐transfected WT human cells exhibited an RT block at position 26 of tRNA‐Met‐CAU and mt-tRNA-Ile-UAU indicative of the m2,2G modification (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, Lane 1). No read‐through product was detected for either tRNA in control human cells indicating that nearly all endogenous tRNA‐Met‐CAU and mt-tRNA-Ile-UAU is modified with m2,2G. Consistent with this observation, increased expression of full-length TRMT1 or variants in control 239T cells had no detectable effect on m2,2G modification in tRNA‐Met‐CAU or mt-tRNA-Ile-UAU (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lanes 2 through 5).</p><p>As expected, the m2,2G modification was absent in tRNA‐Met‐CAU and mt-tRNA-Ile-UAU isolated from the vector‐transfected TRMT1‐KO cell line leading to read‐through to the next RT block (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lane 6). Re‐expression of full-length TRMT1 or TRMT1-Q530N in the TRMT1‐KO cell line was able to restore m2,2G formation in both tRNA-Met-CAU and mt-tRNA-Ile-UAU (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lanes 7 and 9). However, neither the N- nor C-terminal TRMT1 fragment was able to restore m2,2G formation in the tRNAs of the TRMT1‐KO cell line (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lanes 8 and 10). These results indicate that cleavage of TRMT1 by Nsp5 leads to protein fragments that are inactive for tRNA modification activity.</p><p>In addition to TRMT1 activity, we compared the subcellular localization pattern of full-length TRMT1 to the TRMT1 cleavage fragments. To visualize TRMT1, we transiently transfected 293T human cells with constructs expressing human TRMT1 fused at its carboxy terminus to GFP. As a mitochondria marker, we co-expressed a red fluorescent protein fused to the mitochondria targeting signal of pyruvate dehydrogenase (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, Mito-RFP). Full-length TRMT1-GFP exhibited cytoplasmic localization along with a punctate signal in the nucleus (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, TRMT1-WT, GFP). The fluorescence signal for TRMT1 in the cytoplasm overlapped partially with the RFP-tagged mitochondrial marker (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, Merge, yellow signal). The mitochondrial and nuclear localization pattern of full-length TRMT1 is consistent with prior studies demonstrating the presence of a mitochondrial targeting signal and nuclear localization signal in TRMT1 (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). The N-terminal TRMT1 fragment exhibited primarily cytoplasmic localization with a greatly reduced signal in the nucleus, consistent with a lack of the nuclear localization signal at the C-terminus (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, TRMT1 N-term, GFP, merge). In contrast to the N-terminal TRMT1 fragment, the C-terminal TRMT1 fragment displayed primarily nuclear localization with very little signal in the cytoplasm (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, TRMT1 C-term, GFP, merge). These results suggest that TRMT1 in the cytoplasm is the likely target of Nsp5 cleavage with the cleavage fragments displaying altered localization compared to full-length TRMT1.</p></sec><sec id="s2-5"><title>TRMT1-deficient human cells exhibit reduced levels of SARS-CoV-2 RNA replication</title><p>We next investigated whether TRMT1 expression impacts SARS-CoV-2 replication by infecting the 293T control-wild-type (WT) or TRMT1-KO human cell lines described above with SARS-CoV-2. To render the 293T cell lines permissive for SARS-CoV-2 infection, the cell lines were engineered to stably express the ACE2 receptor from an integrated lentiviral vector (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Immunoblotting for the SARS-CoV-2 nucleocapsid protein confirmed that SARS-CoV-2 could infect both the control-WT and TRMT1-KO human cell lines expressing ACE2 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Using these cell lines, we first monitored the effect of SARS-CoV-2 infection on TRMT1 levels. As expected, there was no detectable TRMT1 in any of the lanes containing lysate from the TRMT1-KO cell line (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, compare control-WT, lanes 1–3, to TRMT1-KO, lanes 4–6). In the control-WT cells, we detected a decrease in TRMT1 levels at both multiplicity of infection (MOI) of 0.2 and 0.4 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, TRMT1, quantified in <xref ref-type="fig" rid="fig6">Figure 6B</xref>). The decrease in TRMT1 in SARS-CoV-2-infected 293T cells is comparable to the reduction in TRMT1 levels in MRC5-ACE2 human cell lines infected with SARS-CoV-2 (<xref ref-type="fig" rid="fig1">Figure 1</xref>). We also compared the levels of endogenous TRMT1 after infection with SARS-CoV-2 at a higher MOI of 5.0. Human 293T cells infected at the higher MOI exhibited a reduction in TRMT1 levels to nearly the background of the TRMT1-KO cell lines (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). These results indicate that SARS-CoV-2 infection can induce a drastic reduction in cellular TRMT1 levels.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The expression of tRNA methyltransferase 1 (TRMT1) affects the levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA replication in human cells.</title><p>(<bold>A</bold>) Immunoblot of lysates prepared from 293T control-wild-type (WT) or TRMT1-knockout (KO) cell lines that were mock-infected (multiplicity of infection, MOI of 0) or infected with SARS-CoV-2 at MOI of 0.2 or 0.4 for 24 hr. The immunoblot was probed with antibodies against TRMT1 or actin. Circle represents endogenous full-length TRMT1. Asterisk (*) denotes a non-specific band. Size markers to the right in kiloDalton. (<bold>B</bold>) Normalized TRMT1 signal intensity relative to mock-infected cells (MOI of 0). Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons test. (<bold>C</bold>) Immunoblot of lysates prepared from 293T control-wild-type (WT) or TRMT1-KO cell lines that were mock-infected (MOI of 0) or infected with SARS-CoV-2 at MOI of 0.1 or 5.0 for 24 hr. The immunoblot was probed with antibodies as in (<bold>A</bold>). (<bold>D</bold>) Normalized TRMT1 signal intensity relative to mock-infected cells (MOI of 0). (<bold>E, F</bold>) SARS-CoV-2 RNA copy number in control-WT or TRMT1-KO human 293T cell lines after infection at the indicated MOI for 24 hr. Viral copy number was measured by QRT-PCR and normalized to GAPDH. Samples were measured in triplicate. Statistical significance was determined by two-way ANOVA with Šídák’s multiple comparisons test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, non-significant.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig6-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>QRT-PCR measurements of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90316-fig6-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Human 293T cell lines expressing ACE2 can be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</title><p>(<bold>A</bold>) Immunoblot analysis of lysates prepared from the indicated 293T cell lines expressing empty vector or ACE2. The immunoblot was probed with anti-ACE2 and actin. (<bold>B</bold>) Immunoblot analysis of lysates prepared from 293T-ACE2 cell lines that were mock-infected (multiplicity of infection, MOI 0) or infected with SARS-CoV-2 at the indicated MOI. The blot was probed against the SARS-CoV-2 nucleocapsid (<bold>N</bold>) and actin.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig6-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig6-figsupp1-v2.tif"/></fig></fig-group><p>The ACE2-expressing cell lines were then infected at low or high multiplicity of infection (MOI) followed by harvesting of cells at 24 hr post-infection. Intracellular viral RNA levels were monitored by quantitative RT-PCR of the SARS-CoV-2 envelope protein gene. As expected, titration of SARS-CoV-2 viral particles at either low or high MOI led to a concomitant increase in viral RNA in both control and TRMT1-KO cell lines (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>). Notably, TRMT1-KO cells exhibited a ~three to fourfold reduction in viral RNA compared to control cells infected at the same MOI (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>). These results suggest that expression of TRMT1 is necessary for efficient SARS-CoV-2 replication in human cells.</p><p>To confirm that TRMT1-deficiency is the cause of the reduced SARS-CoV-2 replication, we generated TRMT1-KO cell lines re-expressing TRMT1-WT or TRMT1-Q530N with a C-terminal FLAG tag from an integrated lentiviral construct. As expected, wild-type control 293T cells expressed endogenous TRMT1 that was absent in the TRMT1-KO cell lines with empty vector (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, TRMT1, lanes 1 and 2). Furthermore, we could detect re-expression of TRMT1-WT or TRMT1-Q530N in the TRMT1-KO cell lines containing the integrated lentiviral TRMT1 expression vectors (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, TRMT1, lanes 3–6). We also validated the cell lines by checking for cleavage of the re-expressed TRMT1 by Nsp5. Indeed, the N-terminal TRMT1 cleavage product was detected in the lysate of TRMT1-KO cells expressing TRMT1-WT and Nsp5, but not TRMT1-Q530N and Nsp5 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, TRMT1, compare lanes 3 and 4). These results further support our findings described above that Nsp5 expression leads to site-specific cleavage of TRMT1 in human cells.</p><p>We then expressed the ACE2 receptor in the complemented TRMT1-KO cell lines to render them permissive for SARS-CoV-2 infection (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). Using these cell lines, we first tested the effect of SARS-CoV-2 infection on TRMT1 levels. Compared to mock-infection, TRMT1 protein levels decreased in the TRMT1-KO cell lines expressing TRMT1-WT after infection with SARS-CoV-2 (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, lanes 1–3; quantified in 7B). Notably, the level of TRMT1 was not appreciably changed in the TRMT1-KO cell line expressing TRMT1-Q530N after infection with SARS-CoV-2 (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, lanes 4–6; quantified in 7 C). These results provide evidence that the decrease in endogenous TRMT1 levels after SARS-CoV-2 infection is due to cleavage of TRMT1 by Nsp5.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>tRNA methyltransferase 1 (TRMT1) is required for efficient severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in human cells.</title><p>(<bold>A</bold>) Immunoblot of lysates prepared from the indicated 293T TRMT1-knockout (KO) cell lines that were mock-infected (multiplicity of infection, MOI of 0) or infected with SARS-CoV-2 for 24 hr. The immunoblot was probed with antibodies against TRMT1 or actin. Square represents full-length TRMT1-FLAG. Asterisk (*) denotes a non-specific band. Size markers to the left in kiloDalton. (<bold>B</bold>) Normalized TRMT1-WT signal intensity relative to mock-infected cells (MOI of 0). (<bold>C</bold>) Normalized TRMT1-Q530N signal intensity relative to mock-infected cells (MOI of 0). Statistical significance was determined in (<bold>B</bold>) and (<bold>C</bold>) by one-way ANOVA with Dunnett’s multiple comparisons test. (<bold>D</bold>) SARS-CoV-2 RNA copy number in control-wild-type (WT) or TRMT1-KO human 293T cell lines after infection at the indicated MOI. Viral copy number was measured by QRT-PCR and normalized to GAPDH. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test. *p&lt;0.05; **p&lt;0.01; ****p&lt;0.0001; ns, non-significant.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig7">Figure 7A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig7-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>QRT-PCR measurements of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA for <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90316-fig7-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Expression of nonstructural protein 5 (Nsp5) leads to cleavage of tRNA methyltransferase 1 (TRMT1)-wild-type (WT) re-expressed in TRMT1-knockout (KO) cells, but not TRMT1-Q530N.</title><p>Immunoblot of lysates from human cells integrated with empty lentiviral vector or lentiviral expression vectors for wild-type (WT) TRMT1 or TRMT1-Q530N. The cell lines were transfected with either a vector or a construct expressing Nsp5-Strep. The immunoblot was probed with anti-TRMT1, Strep, and actin antibodies. Square represents TRMT1-FLAG, circle represent endogenous TRMT1, Asterisk (*) denotes a non-specific band, and arrow represents N-terminal TRMT1 cleavage product.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig7-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Immunoblot analysis of lysates prepared from the indicated 293T cell lines expressing empty vector or ACE2.</title><p>The immunoblot was probed with anti-ACE2 and actin.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Raw uncropped immunoblots for <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-90316-fig7-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig7-figsupp2-v2.tif"/></fig></fig-group><p>We next measured SARS-CoV-2 RNA levels after infecting the TRMT1-KO cell lines with SARS-CoV-2. Reproducing our results above, we found that the TRMT1-KO+vector cell line exhibited a decrease in viral RNA levels compared to control cells infected at the same MOI (<xref ref-type="fig" rid="fig7">Figure 7D</xref>, compare control +vec to KO +vec). TRMT1-KO cell lines re-expressing TRMT1 exhibited higher viral RNA production relative to the TRMT1-KO+vector cell line that was comparable to the control-WT cells (<xref ref-type="fig" rid="fig7">Figure 7D</xref>, compare KO +vec to KO +WT). Notably, the TRMT1-KO cell line expressing TRMT1-Q530N exhibited a higher level of viral RNA production compared to the TRMT1-KO cell line expressing TRMT1-WT at higher MOI (<xref ref-type="fig" rid="fig7">Figure 7</xref>, KO +Q530 N). Altogether, these results uncover a requirement for TRMT1 expression for efficient SARS-CoV-2 replication in human cells.</p></sec><sec id="s2-6"><title>Impact of TRMT1 on SARS-CoV-2 particle infectivity</title><p>Since the presence or absence of TRMT1 appears to impact SARS-CoV-2 RNA production in human 293T cells, we tested if this phenomenon could alter viral particle production. To this end, we collected tissue culture media supernatant containing viral particles generated from control-WT or TRMT1-KO cell lines that were infected by SARS-CoV-2 for 24 hr. The viral titer of the supernatant was determined by focus forming unit assay and particle infectivity expressed relative to viral genomic RNA copy number within the same sample. Consistent with the reduced levels of viral RNA in TRMT1-KO cells infected with SARS-CoV-2, the supernatant from infected TRMT1-KO cells exhibited reduced titer and slightly lower infectivity when compared to viral particles produced from control-WT cells (<xref ref-type="fig" rid="fig8">Figure 8</xref>, control-WT versus TRMT1-KO). Re-expression of TRMT1 in the TRMT1-KO cells partially restored viral titer at the lower MOI and increased infectivity compared to supernatants from TRMT1-KO cell lines (<xref ref-type="fig" rid="fig8">Figure 8</xref>, TRMT1-KO+vec versus TRMT1-KO+WT). Interestingly, the expression of the non-cleavable TRMT1-Q530N variant in TRMT1-KO cells promoted an increase of viral titer as well as infectivity compared to expression of wild-type TRMT1 (<xref ref-type="fig" rid="fig8">Figure 8</xref>, TRMT1-KO+WT versus TRMT1-KO+Q530 N). Altogether, these observations suggest an unexpected role for TRMT1 expression in virus production and the generation of optimally infectious SARS-CoV-2 particles.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Viral infectivity measurement of supernatants collected from the indicated cell lines infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for 24 hr.</title><p>(<bold>A</bold>) Viral titer of supernatants collected from the indicated cell lines infected with SARS-CoV-2. Infectious titer was determined by TCID<sub>50</sub> endpoint dilution assay in VeroE6 cells and expressed in focus forming units per mL of supernatant (FFU/mL). (<bold>B</bold>) Infectivity of SARS-CoV-2 particles generated from cell lines in (<bold>A</bold>). Infectivity of viral particles was calculated with the formula [(FFU/mL)/(viral genomic RNA copies/mL)], and expressed in FFU per 100 genomic copies.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Infectious titers and QRT-PCR results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90316-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90316-fig8-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we demonstrate that TRMT1 tRNA modification enzyme is an endogenous cleavage target of the SARS-CoV-2 main protease. Our studies parallel the simultaneous work by D’Oliviera et al. that has elucidated how the SARS-CoV-2 main protease recognizes the TRMT1 cleavage sequence (<xref ref-type="bibr" rid="bib12">D Oliviera et al., 2023</xref>). D’Oliviera et al. have determined the structural basis for recognition of TRMT1 by the SARS-CoV-2 main protease, which has revealed a distinct binding mode for certain substrates of the main protease, including TRMT1. Together, our study and the investigation by D’Oliviera et al. provide independent corroboration of each other’s main conclusion that TRMT1 is recognized and cleaved by the SARS-CoV-2 main protease in a sequence-specific manner. Moreover, after our manuscript and the manuscript by D’Oliviera et al. were deposited on <italic>BioRxiv</italic>, an independent study by <xref ref-type="bibr" rid="bib41">Lu and Zhou, 2023</xref> has further confirmed our findings that the SARS-CoV-2 main protease can cleave TRMT1.</p><p>TRMT1 could represent a coincidental substrate of Nsp5 during SARS-CoV-2 infection due to the presence of a sequence matching the cleavage site of SARS-CoV-2 polyproteins. Since the majority of TRMT1 exhibits steady-state localization to the nucleus and mitochondria of multiple human cell types (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>), Nsp5 could have access mainly to newly synthesized TRMT1 in the cytoplasm. Moreover, the effect of SARS-CoV-2 infection on TRMT1 levels could depend on the concentration of TRMT1, half-life of TRMT1, and/or amount of Nsp5 expression in the infected cell. This could account for the observation that TRMT1 levels are reduced but not abolished in human cells infected with SARS-CoV-2. Consistent with our results, a subset of proteomic studies has found decreased TRMT1 protein levels in SARS-CoV-2-infected human cells as well as in post-mortem tissue samples from deceased COVID-19 patients (<xref ref-type="bibr" rid="bib4">Bojkova et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Nie et al., 2021</xref>). These findings suggest that SARS-CoV-2 infection could impact TRMT1 protein levels and tRNA modification patterns within the cells of an infected individual.</p><p>While TRMT1 cleavage could be a collateral effect of SARS-CoV-2 infection, the subsequent impact on tRNA modification levels could have physiological consequences on downstream molecular processes that ultimately affect cellular health and/or viral replication. We have previously shown that TRMT1-deficient human cells exhibit decreased levels of global protein synthesis, perturbations in redox metabolism, and reduced proliferation (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). Moreover, we have found that partial depletion of TRMT1 is sufficient to increase the oxidative stress sensitivity of human neural stem cells. Thus, the reduction in TRMT1 and TRMT1-catalyzed tRNA modifications observed in human lung cells upon SARS-CoV-2 infection could lead to changes in protein synthesis that affects cellular proliferation and metabolism. In lung tissues, the disruption of TRMT1-dependent processes caused by changes in TRMT1-catalyzed tRNA modification levels could contribute to the pathophysiological outcomes associated with COVID-19 disease. Consistent with this possibility, TRMT1 has been identified as a prognosis factor for SARS-CoV-2 disease severity (<xref ref-type="bibr" rid="bib39">Li et al., 2021b</xref>).</p><p>We have found that human cells deficient in TRMT1 display reduced viral RNA levels compared to wild-type cells after SARS-CoV-2 infection. This finding suggests that TRMT1 expression is required for efficient SARS-CoV-2 replication. As mentioned above, TRMT1-deficient human cells exhibit an overall reduction in global protein synthesis due to the loss of m2,2G modifications in tRNAs (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). Thus, the TRMT1-deficient human cells could present a cellular environment that is unable to support the levels of translation necessary for efficient virus production. In addition, TRMT1-deficient human cells could exhibit changes in gene expression and cellular metabolism that are suboptimal for SARS-CoV-2 replication.</p><p>While TRMT1 could be an unintentional target of Nsp5, it remains conceivable that TRMT1 cleavage modulates the SARS-CoV-2 life cycle through an uncharacterized process. One possibility is that viral RNAs could be substrates of TRMT1-catalyzed RNA methylation. Previous studies have found that endogenous host RNA modification enzymes can modify the genomic and sub-genomic RNAs of SARS-CoV-2 (<xref ref-type="bibr" rid="bib5">Burgess et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Di Giorgio et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Li et al., 2021a</xref>; <xref ref-type="bibr" rid="bib57">Peng et al., 2022</xref>; <xref ref-type="bibr" rid="bib83">Zhang et al., 2021a</xref>). Moreover, uncharacterized modifications have been identified through Nanopore sequencing in the genomic and subgenomic RNAs of SARS-CoV-2 (<xref ref-type="bibr" rid="bib30">Kim et al., 2020</xref>). There could be portions of the SARS-CoV-2 genome or subgenomic RNAs that fold into substrates that resemble tRNA targets of TRMT1. There has been precedence for the folding of certain segments of plant viral RNAs into tRNA-like structures that can be modified by cellular tRNA modification enzymes (<xref ref-type="bibr" rid="bib1">Baumstark and Ahlquist, 2001</xref>; <xref ref-type="bibr" rid="bib2">Becker et al., 1998</xref>; <xref ref-type="bibr" rid="bib37">Lesiewicz and Dudock, 1978</xref>). Moreover, the N-terminal TRMT1 fragment could gain the ability to modify viral RNAs due to altered binding specificity since the N-terminal TRMT1 fragment retains the entire methyltransferase domain but not the Zn-finger motif involved in tRNA interaction. Future studies will examine for possible interactions between TRMT1 and the SARS-CoV-2 transcriptome as well as the presence of TRMT1-catalyzed modifications in SARS-CoV-2 RNAs.</p><p>We have previously found that TRMT1-deficient human cells exhibit nearly undetectable m2,2G without a major impact on other RNA modifications (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). In contrast, human cells infected with SARS-CoV-2 exhibited a decrease in multiple RNA modifications present in a variety of RNAs, including tRNA, rRNA, snRNA, and mRNA. Thus, the widespread changes in RNA modifications after infection with SARS-CoV-2 suggest that coronavirus infection could alter the levels or activity of multiple RNA modification enzymes in addition to TRMT1. Consistent with this hypothesis, RNA modification profiles are changed in response to various forms of cellular stress, including viral infection (<xref ref-type="bibr" rid="bib7">Chan et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Jungfleisch et al., 2022</xref>). Overall, the study presented here highlights the expanding role of RNA modifications in modulating cellular responses to pathogens that will be the important subject of further investigation.</p><sec id="s3-1"><title>Ideas and speculation</title><p>Our findings suggest that the SARS-CoV-2 might self-limit its replication by altering the host translation machinery through TRMT1 degradation and reduced levels of m2,2G-modified tRNAs. This perturbation of the tRNA pool may further inhibit host translation that is already targeted by Nsp1 blockade of mRNA entry on 40 S ribosomes (<xref ref-type="bibr" rid="bib28">Kamitani et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Lapointe et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Schubert et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Thoms et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Tidu et al., 2020</xref>). The inhibition of host translation may be beneficial to certain viruses that can locally maintain a tRNA pool optimized for viral translation (<xref ref-type="bibr" rid="bib22">Hernandez-Alias et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Pavon-Eternod et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">van Weringh et al., 2011</xref>; <xref ref-type="bibr" rid="bib81">Yang et al., 2021</xref>). Another possibility is that Nsp5-TRMT1 interaction facilitates the packaging of specific tRNAs into viral particles as suggested previously (<xref ref-type="bibr" rid="bib56">Peña et al., 2022</xref>). The observation that expression of the non-cleavable TRMT1-Q530N variant enhances viral replication and infectivity supports the hypothesis that TRMT1 could facilitate tRNA uptake into viral particles. The packaging of specific tRNAs in viral particles could augment viral translation in the subsequent round of infection, thereby enhancing infectivity and perhaps facilitating the species jump of SARS-CoV-2 towards hosts with incompatible codon bias.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>, female)</td><td align="char" char="." valign="bottom">293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">ATCC: CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>, male)</td><td align="left" valign="bottom">MRC5 +ACE2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">Raymonda et al., 2022</xref></td><td align="left" valign="bottom">ATCC: CCL-171</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain (coronavirus)</td><td align="left" valign="bottom">SARS-CoV-2</td><td align="left" valign="bottom">BEI resources</td><td align="left" valign="bottom">NR-52282</td><td align="left" valign="bottom">Isolate Hong Kong/VM20001061/2020</td></tr><tr><td align="left" valign="bottom">Strain (coronavirus)</td><td align="left" valign="bottom">SARS-CoV-2</td><td align="left" valign="bottom">European Virus Archive</td><td align="char" char="." valign="bottom">014 V-03890</td><td align="left" valign="bottom">Isolate BetaCoV/France/<break/>IDF0372/2020</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNA Clean &amp; Concentrator-5 kit</td><td align="left" valign="bottom">Zymo</td><td align="left" valign="bottom">R1013</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">Dotmatics</td><td align="left" valign="bottom">Prism 10, version 10.2.2 (341)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Chimera</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">Pettersen et al., 2004</xref></td><td align="left" valign="bottom">X-1.6.1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>TRMT1</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID: 55621</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pcDNA3.1-TRMT1-FLAG</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fu Lab plasmid, mammalian expression vector for wild-type TRMT1 fused to FLAG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pcDNA3.1-TRMT1-GFP</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fu Lab plasmid, mammalian expression vector for wild-type TRMT1 fused to GFP</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pcDNA3.1-TRMT1-FLAG-Q530N</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fu Lab plasmid, mammalian expression vector for TRMT1-Q530N variant fused to FLAG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pcDNA31.-TRMT1-FLAG-N-term</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fu Lab plasmid, mammalian expression vector for N-terminal TRMT1 fragment fused to FLAG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pcDNA31.-TRMT1-FLAG-C-term</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fu Lab plasmid, mammalian expression vector for C-terminal TRMT1 fragment fused to FLAG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pLenti-CMV-GFP-Blast</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene_#17445">Addgene #17445</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pLenti-CMV-TRMT1-FLAG</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fu Lab plasmid, lentiviral expression vector for wild-type TRMT1 fused to FLAG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pLenti-CMV-TRMT1-FLAG-Q530N</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fu Lab plasmid, lentiviral expression vector for TRMT1-Q530N fused to FLAG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">psPAX2</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene_#12260">Addgene # 12260</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">pMD2.G</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene_#12259">Addgene #12259</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">MagSTREP ‘type3’ XT beads, 5% suspension</td><td align="left" valign="bottom">IBA Lifesciences</td><td align="char" char="hyphen" valign="bottom">2-4090-002</td><td align="left" valign="bottom">For protein purification</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DYKDDDDK-Tag Monoclonal Antibody Magnetic Microbead</td><td align="left" valign="bottom">Syd Labs</td><td align="left" valign="bottom">PA004830</td><td align="left" valign="bottom">For protein purification</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-TRMT1 aa 201–229 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnologies</td><td align="left" valign="bottom">G3, sc-373687</td><td align="left" valign="bottom">Western blot (1:1,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-TRMT1 aa 609–659 (rabbit polyclonal)</td><td align="left" valign="bottom">Bethyl</td><td align="left" valign="bottom">A304-205A</td><td align="left" valign="bottom">Western blot (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IBA LifeSciences StrepMAB-Classic (mouse monoclonal)</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">NC9261069</td><td align="left" valign="bottom">Western blot (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ANTI-FLAG M2 (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">F3165</td><td align="left" valign="bottom">Western blot (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-SARS-CoV-2 nucleoprotein N protein (Rabbit polyclonal)</td><td align="left" valign="bottom">Sino Biological</td><td align="char" char="hyphen" valign="bottom">40068-RP01</td><td align="left" valign="bottom">Western blot (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-actin C4 (Mouse monoclonal)</td><td align="left" valign="bottom">EMD Millipore</td><td align="left" valign="bottom">MAB1501</td><td align="left" valign="bottom">Western blot (1:1,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IRDye 800CW anti-mouse IgG (goat polyclonal)</td><td align="left" valign="bottom">Fisher Scientific</td><td align="char" char="ndash" valign="bottom">925–32210</td><td align="left" valign="bottom">Western blot secondary (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IRDye 680RD anti-Mouse IgG (Goat polyclonal)</td><td align="left" valign="bottom">Li-COR</td><td align="char" char="ndash" valign="bottom">925–68070</td><td align="left" valign="bottom">Western blot secondary (1:10,000)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Odyssey Imager instrument</td><td align="left" valign="bottom">Li-Cor</td><td align="left" valign="bottom">CLx</td><td align="left" valign="bottom">For imaging infrared dye immunoblots.</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Image Studio</td><td align="left" valign="bottom">Li-Cor</td><td align="left" valign="bottom">Version 5.2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji (Fiji is just ImageJ)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib65">Schindelin et al., 2012</xref></td><td align="left" valign="bottom">Release 2.15.1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent (plasmid)</td><td align="left" valign="bottom">RRL.sin.cPPT.SFFV/<break/>Ace2.WPRE (MT136)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Rebendenne et al., 2021</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene_#145842">Addgene 145842</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-ACE2 Antibody (Goat polyclonal)</td><td align="left" valign="bottom">R&amp;D systems</td><td align="left" valign="bottom">AF933</td><td align="left" valign="bottom">Western blot (1:200)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SARS_For</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">QRT-PCR</td><td align="left" valign="bottom"><named-content content-type="sequence">ACAGGTACGTTAATAGTTAATAGCGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SARS_Rev</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">QRT-PCR</td><td align="left" valign="bottom"><named-content content-type="sequence">ATATTGCAGCAGTACGCACACA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAPDH_For</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">QRT-PCR</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTCACCGGCATGGCCTTTCGCGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAPDH_Rev</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">QRT-PCR</td><td align="left" valign="bottom"><named-content content-type="sequence">TGGAGGAGTGGGTGTCGCTGTTGA</named-content></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines</title><p>293T and MRC-5 cell lines were obtained from ATCC and authenticated by STR profiling. 293T human embryonic cell lines were cultured in Dulbecco’s Minimal Essential Medium (DMEM) containing 10% fetal bovine serum, 2 mM L-alanyl-L-glutamine (GlutaMax, Gibco) and 1% Penicillin/Streptomycin. Cells were grown at 37 °C, 20% Oxygen, and 5% CO<sub>2</sub>. Telomerase-immortalized MRC5 fibroblasts expressing ACE2 (MRC5-ACE2 cells) were cultured in Dulbecco’s modified Eagle serum (DMEM; Invitrogen) supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Atlanta Biologicals), 4.5 g/L glucose, and 1% penicillin-streptomycin (Pen-Strep; Life Technologies) at 37 °C in a 5% (vol/vol) CO2 atmosphere. The cell lines were authenticated by STR DNA profiling and confirmed negative for mycoplasma contamination by Labcorp (<ext-link ext-link-type="uri" xlink:href="https://celllineauthentication.labcorp.com">https://celllineauthentication.labcorp.com</ext-link>).</p></sec><sec id="s4-2"><title>SARS-CoV-2 infection of human cells for protein and RNA analysis</title><p>The SARS-CoV-2 isolate, Hong Kong/VM20001061/2020, was previously isolated from a nasopharyngeal aspirate and throat swab from an adult male patient in Hong Kong and was obtained through BEI resources (NR-52282). Viral stocks of SARS-CoV-2 were propagated in Vero-E6 cells in MEM supplemented with 2% (vol/vol) FBS, 4.5 g/L glucose, 1 X Glutamax and 1% penicillin-streptomycin at 37 °C. Viral stock titers were determined by TCID50 analysis in Vero-E6 cells. Experiments involving live SARS-CoV-2 were conducted in a biosafety level 3 facility at the University of Rochester.</p><p>For infection, MRC5-ACE2 cells were grown in six-well plates to 90% confluence in growth medium (MRC5-ACE2: DMEM supplemented with 10% FBS and 1% Pen-Strep). Prior to infection, cells were washed with 1 mL of DMEM supplemented with 2% FBS and 1% Pen-Strep. For infection, 750 μL of viral master mix (MOI=5) was added to each well for 1.5 hr. After the adsorption period, the medium was removed and replaced with fresh DMEM supplemented with 2% FBS and 1% Pen-Strep. To harvest protein, the cell monolayer was washed with 1 mL cold PBS and cells were scraped into 250 μL disruption buffer (250 mM Tris-HCl Ph 7.4, 10% glycerol, 2% β-mercaptoethanol, 5% SDS). DNA was sheared using a sonication probe and samples were stored at –20 °C. To harvest RNA, the medium was removed, and the monolayer was washed with PBS. Cells were collected in 400 μL Trizol and stored at –80 °C.</p></sec><sec id="s4-3"><title>Liquid chromatography-mass spectrometry of nucleosides</title><p>Total RNA was isolated using Trizol RNA extraction. Small RNAs were subsequently purified from total RNA using the Zymo RNA Clean &amp; Concentrator-5 kit. Small RNAs (1 μg) was digested and analyzed by LC-MS as previously described (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="bib6">Cai et al., 2015</xref>). Briefly, ribonucleosides were separated using a Hypersil GOLD C18 Selectivity Column (Thermo Scientific) followed by nucleoside analysis using a Q Exactive Plus Hybrid Quadrupole-Orbitrap. The modification difference ratio was calculated using the m/z intensity values of each modified nucleoside following normalization to the sum of intensity values for the canonical ribonucleosides; A, U, G, and C. Statistical analysis of the mass spectrometry results was performed using GraphPad Prism software with error bars representing the standard deviation. Statistical tests and the number of times each experiment was repeated are noted in the figure legend. Raw intensity values for each measured nucleoside are provided in the source data file.</p></sec><sec id="s4-4"><title>In silico analysis of TRMT1 structure</title><p>The Nsp5 cleavage site sequence logo was generated using: <ext-link ext-link-type="uri" xlink:href="https://weblogo.berkeley.edu/logo.cgi">https://weblogo.berkeley.edu/logo.cgi</ext-link>.</p><p>The predicted tertiary structure of human TRMT1 (Uniprot Q9NXH9) was determined using AlphaFold. Structural visualization was performed using UCSF Chimera software developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (<xref ref-type="bibr" rid="bib59">Pettersen et al., 2004</xref>). The PDB file for the predicted TRMT1 structures has been provided in the source file.</p></sec><sec id="s4-5"><title>Plasmid constructs</title><p>The pcDNA3.1-TRMT1-FLAG and pcDNA3.1-TRMT1-GFP expression plasmids have been described previously (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). The pcDNA3.1-TRMT1-FLAG-Q530N expression construct was generated by DpnI site-directed mutagenesis. The pcDNA3.1 expression plasmids encoding the N- and C-terminal TRMT1 fragments were generated by PCR cloning. Lentiviral constructs expressing TRMT1-WT or TRMT1-Q530N were generated by T5 Exonuclease DNA Assembly (TEDA) of PCR fragments into pLenti-CMV-GFP-Blast (Addgene 17445) (<xref ref-type="bibr" rid="bib79">Xia et al., 2019</xref>). All plasmid constructs were verified by Sanger sequencing and whole plasmid sequencing (Plasmidsaurus).</p></sec><sec id="s4-6"><title>Generation of human cell lines by lentiviral integration</title><p>For lentivirus production, 1×10<sup>6</sup> 293 T cells were seeded onto 60 mm tissue culture dishes. After 24 hr, 1.5 μg of pLenti CMV Blast plasmids containing empty vector or TRMT1 along with 1.5 μg of psPAX2 packaging plasmid and 0.7 μg of pMD2.G envelope plasmid was transfected into the 293T cells using calcium phosphate transfection. Media was changed 16 hr post-transfection. At 48 hr post-transfection, the media containing virus was collected, filter sterilized through a 0.45 μm filter, flash frozen, and stored at –80 °C.</p><p>For lentiviral infection of 293T cell lines, 1×10<sup>6</sup> cells were seeded onto 60 mm tissue culture dishes. After 24 hr, 1 mL of either virus or media for mock infection along with 2 mL of media supplemented with 10 μg/mL of polybrene was added to each well. The cells were washed with PBS and fed fresh media 24 hr post-infection. Polyclonal cell lines with stable integration of the lentiviral constructs were selected with 15 μg/mL blasticidin.</p></sec><sec id="s4-7"><title>Transient transfection, protein purification, and immunoblotting</title><p>Transient transfection and cellular extract production were performed as previously described (<xref ref-type="bibr" rid="bib16">Fu et al., 2010</xref>). Briefly, 2.5×10<sup>6</sup> 293 T HEK cells were transiently transfected by calcium phosphate DNA precipitation with 10–20 μg of plasmid DNA. Cells were harvested by trypsinization and washed once with PBS. The cell pellet was resuspended in 500 μL hypotonic lysis buffer (20 mM HEPES, pH 7.9; 2 mM MgCl<sub>2</sub>; 0.2 mM EGTA, 10% glycerol, 0.1 mM PMSF, 1 mM DTT), incubated on ice for 5 min and subjected to three freeze-thaw cycles in liquid nitrogen and 37 °C. NaCl was added to extracts to a final concentration of 400 mM. After centrifugation at 14,000 x g for 15 min at 4 °C, an equal amount of hypotonic lysis buffer with 0.2% NP-40 was added to 500 μL of soluble cellular extract.</p><p>Protein purification from human cell extracts was carried out as previously described with minor adjustments (<xref ref-type="bibr" rid="bib35">Lentini et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Lentini et al., 2022</xref>). For Strep-tag purification, whole cell extract from transiently transfected cells cell lines (1 mg of total protein) was rotated for 2 hr at 4 ° C in lysis buffer (20 mM HEPES at pH 7.9, 2 mM MgCl2, 0.2 mM EGTA, 10% glycerol, 1 mM DTT, 0.1 mM PMSF, 0.1% NP-40) with 200 mM NaCl. Resin was washed three times using the same buffer followed by protein analysis. Strep-tagged proteins were purified using MagSTREP ‘type3’ XT beads, 5% suspension (IBA Lifesciences), and eluted with desthiobiotin. FLAG-tagged proteins were purified by incubating whole cell lysates from the transfected cell lines with 20 μL of DYKDDDDK-Tag Monoclonal Antibody Magnetic Microbead (Syd Labs) for 3 hr at 4 °C. Magnetic resin was washed three times in hypotonic lysis buffer with 200 mM NaCl.</p><p>Immunoblotting was performed as previously described (<xref ref-type="bibr" rid="bib60">Ramos et al., 2019</xref>). Briefly, cell extracts and purified protein samples were boiled at 95 °C for 5 min followed by fractionation on NuPAGE Bis-Tris polyacrylamide gels (Thermo Scientific). Separated proteins were transferred to Immobilon FL polyvinylidene difluoride (PVDF) membrane (Millipore) for immunoblotting. Membrane was blocked by Odyssey blocking buffer for 1 hrr at room temperature followed by immunoblotting with the following antibodies: mouse monoclonal anti-TRMT1 aa 201–229 (G3, sc-373687, Santa Cruz Biotechnologies), rabbit polyclonal anti-TRMT1 aa 609–659 (Bethyl, A304-205A); anti-Strep-tag II (NC9261069, Thermo Fisher), anti-FLAG epitope tag (L00018; F3165), Rabbit polyclonal anti-SARS-CoV-2 nucleoprotein N protein (40068-RP01; Sino Biological), and anti-actin (L00003; EMD Millipore). Proteins were detected using a 1:10,000 dilution of fluorescent IRDye 800CW goat anti-mouse IgG (925–32210; Thermofisher) or IRDye 680RD Goat anti-Mouse IgG Secondary Antibody (925–68070; Li-COR). Immunoblots were scanned using direct infrared fluorescence via the Odyssey system (LI-COR Biosciences).</p><p>Immunoblots were quantified and analyzed using Image Studio Version 5.2 (Li-Cor Biosciences). Rectangles of the same dimension for a given band were used to measure raw signal intensity in either the 700 or 800 nm channel. The intensity of a band in a lane was normalized to actin as a load control. For quantification of the N-terminal TRMT1 cleavage band, we measured the total signal of both the cleavage band and the non-specific band in all lanes. After normalization to actin, the total signal from the cleavage band and the non-specific band in the control lane from cells expressing GFP was subtracted from the lanes with cells expressing Nsp5 to calculate the signal arising from the cleavage band. Statistical analyses were performed using GraphPad Prism software. Where applicable, error bars represent the standard deviation. Statistical tests and the number of times each experiment was repeated are noted in each figure legend. Original files of the full raw unedited blots are available in the accompanying source data file.</p></sec><sec id="s4-8"><title>RNA analysis by primer extension</title><p>Total RNA was extracted using TRIzol LS reagent (Invitrogen). RNAs were diluted into formamide load buffer, heated to 95 °C for 3 min, and fractionated on a 10% polyacrylamide, Tris-Borate-EDTA (TBE) gel containing 7 M urea. Sybr Gold nucleic acid staining (Invitrogen) was conducted to identify the RNA pattern. For primer extension analysis, 1.5 μg of total RNA was pre-annealed with 5’-<sup>32</sup>P-labeled oligonucleotide and 5 x hybridization buffer (250 mM Tris, pH 8.5, and 300 mM NaCl) in a total volume of 7 μl. The mixture was heated at 95 °C for 3 min followed by slow cooling to 42 °C. An equal amount of extension mix consisting of avian myeloblastosis virus reverse transcriptase (Promega), 5 x AMV buffer, and 40 μM dNTPs was added. The mixture was then incubated at 42 °C for 1 hr and loaded on 15% 7 M urea denaturing polyacrylamide gel. Gels were exposed on a phosphor screen (GE Healthcare) and scanned on a Bio-Rad personal molecular followed by analysis using Fiji NIH ImageJ software (<xref ref-type="bibr" rid="bib65">Schindelin et al., 2012</xref>). Primer extension oligonucleotide sequences were previously described (<xref ref-type="bibr" rid="bib10">Dewe et al., 2017</xref>). Full unedited scan images are available in the accompanying source data file.</p></sec><sec id="s4-9"><title>Subcellular localization</title><p>For localization of TRMT1 tagged with GFP, 293T human cells were seeded onto coverslips in a six-well plate followed by transfection with the GFP plasmids noted above using Lipofectamine 3000 reagent (Thermo Fisher). For mitochondrial localization, the cells were infected with baculovirus expressing RFP targeted to mitochondria (CellLight Mitochondria-RFP, BacMam 2.0, Life Technologies). To visualize the nucleus, Hoechst dye was added to the media for 30 min before the cells were washed with PBS, fixed with 4% formaldehyde, and mounted in Aqua Poly/Mount (Polysciences Inc) followed by imaging on a Nikon A1R HD microscope.</p></sec><sec id="s4-10"><title>Assays for viral replication</title><p>The SARS-CoV-2 was a French Ile de France isolate (<ext-link ext-link-type="uri" xlink:href="https://www.european-virus-archive.com/virus/sars-cov-2-isolate-betacovfranceidf03722020">https://www.european-virus-archive.com/virus/sars-cov-2-isolate-betacovfranceidf03722020</ext-link>). Viral stocks were generated by amplification on VeroE6 cells. The supernatant was collected, filtered through a 0.45 µm membrane, and tittered using a TCID50 assay. For infections, the cells were previously transduced with a Lentiviral vector expressing ACE2 using the lentiviral construct RRL.sin.cPPT.SFFV/Ace2.WPRE (MT136) was kindly provided by Caroline Goujon (Addgene plasmid # 145842) (<xref ref-type="bibr" rid="bib62">Rebendenne et al., 2021</xref>). Seventy-two hours after transduction, accurate ACE2 expression was controlled on western blot probed with anti-ACE2 antibody (Human ACE2 Antibody, AF933, R&amp;D systems). ACE2-positive cells (70–80% confluence) were then infected with SARS-CoV-2 diluted to achieve the desired MOI. After 24 hr in culture, the cells were lysed with the Luna cell ready lysis module (New England Biolabs).</p><p>To measure RNA levels, the amplification reaction was run on a LightcyclerR 480 thermocycler (Roche Diagnostics) using the Luna Universal One-Step RT-qPCR kit (New England Biolabs) with the following primers:</p><list list-type="simple"><list-item><p>SARS_For: 5’-<named-content content-type="sequence">ACAGGTACGTTAATAGTTAATAGCGT</named-content></p></list-item><list-item><p>SARS_Rev: 5’-<named-content content-type="sequence">ATATTGCAGCAGTACGCACACA</named-content></p></list-item><list-item><p>GAPDH_For: 5’-<named-content content-type="sequence">GCTCACCGGCATGGCCTTTCGCGT</named-content></p></list-item><list-item><p>GAPDH_Rev: 5’-<named-content content-type="sequence">TGGAGGAGTGGGTGTCGCTGTTGA</named-content>.</p></list-item></list><p>Each qPCR was performed in triplicate, and the means and standard deviations were calculated. Relative quantification of data obtained from RT-qPCR was used to determine changes in SARS-CoV-2 Envelope (E) gene expression across multiple samples after normalization to the internal reference GAPDH gene. The raw qPCR values are provided in the source data file.</p></sec><sec id="s4-11"><title>SARS-CoV-2 infectivity measurements</title><p>Viral supernatants were collected and filtered on 0.45 µm filters. Virus was then purified by centrifugation through a 20% sucrose cushion at 25,000 rpm for 2.5 hr at 4 °C in a Sw32Ti rotor (Beckman Coulter). Virus pellets were resuspended in PBS and virus genomic RNA copy number was quantified by RTqPCR as described above. Absolute quantification of data obtained from RT-qPCR was used to determine changes in SARS-CoV-2 Envelope (E) gene expression across multiple samples by using external standards of SARS-CoV-2 (dilution 10<sup>7</sup>–10 copies) amplified in parallel within the same instrument run. The raw qPCR values are provided in the source data file. The TCID50 endpoint assay was performed on 96-well plates on VeroE6 cells using the Spearman Karber algorithm (<xref ref-type="bibr" rid="bib9">Cordes et al., 1996</xref>).</p></sec><sec id="s4-12"><title>Material Availability</title><p>All materials, including plasmids and cell lines, are readily available upon request.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Resources, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-90316-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Chenghong Deng, Cailyn Leo, Logan Edvalson, and Sina Ghaemmaghami for comments on this manuscript; the Mass Spectrometry Resource Lab at the University of Rochester; and the Clinical Proteomics Platform, CHU Montpellier.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumstark</surname><given-names>T</given-names></name><name><surname>Ahlquist</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The brome mosaic virus RNA3 intergenic replication enhancer folds to mimic a tRNA TpsiC-stem loop and is modified in vivo</article-title><source>RNA</source><volume>7</volume><fpage>1652</fpage><lpage>1670</lpage><pub-id pub-id-type="pmid">11720293</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>HF</given-names></name><name><surname>Motorin</surname><given-names>Y</given-names></name><name><surname>Florentz</surname><given-names>C</given-names></name><name><surname>Giegé</surname><given-names>R</given-names></name><name><surname>Grosjean</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Pseudouridine and ribothymidine formation in the tRNA-like domain of turnip yellow mosaic virus RNA</article-title><source>Nucleic Acids Research</source><volume>26</volume><fpage>3991</fpage><lpage>3997</lpage><pub-id pub-id-type="doi">10.1093/nar/26.17.3991</pub-id><pub-id pub-id-type="pmid">9705510</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaesius</surname><given-names>K</given-names></name><name><surname>Abbasi</surname><given-names>AA</given-names></name><name><surname>Tahir</surname><given-names>TH</given-names></name><name><surname>Tietze</surname><given-names>A</given-names></name><name><surname>Picker-Minh</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>G</given-names></name><name><surname>Farooq</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Latif</surname><given-names>Z</given-names></name><name><surname>Khan</surname><given-names>MN</given-names></name><name><surname>Kaindl</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutations in the tRNA methyltransferase 1 gene TRMT1 cause congenital microcephaly, isolated inferior vermian hypoplasia and cystic leukomalacia in addition to intellectual disability</article-title><source>American Journal of Medical Genetics. Part A</source><volume>176</volume><fpage>2517</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.38631</pub-id><pub-id pub-id-type="pmid">30289604</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bojkova</surname><given-names>D</given-names></name><name><surname>Klann</surname><given-names>K</given-names></name><name><surname>Koch</surname><given-names>B</given-names></name><name><surname>Widera</surname><given-names>M</given-names></name><name><surname>Krause</surname><given-names>D</given-names></name><name><surname>Ciesek</surname><given-names>S</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Münch</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteomics of SARS-CoV-2-infected host cells reveals therapy targets</article-title><source>Nature</source><volume>583</volume><fpage>469</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2332-7</pub-id><pub-id pub-id-type="pmid">32408336</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>HM</given-names></name><name><surname>Depledge</surname><given-names>DP</given-names></name><name><surname>Thompson</surname><given-names>L</given-names></name><name><surname>Srinivas</surname><given-names>KP</given-names></name><name><surname>Grande</surname><given-names>RC</given-names></name><name><surname>Vink</surname><given-names>EI</given-names></name><name><surname>Abebe</surname><given-names>JS</given-names></name><name><surname>Blackaby</surname><given-names>WP</given-names></name><name><surname>Hendrick</surname><given-names>A</given-names></name><name><surname>Albertella</surname><given-names>MR</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name><name><surname>Stapleford</surname><given-names>KA</given-names></name><name><surname>Wilson</surname><given-names>AC</given-names></name><name><surname>Mohr</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting the m<sup>6</sup>A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication</article-title><source>Genes &amp; Development</source><volume>35</volume><fpage>1005</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1101/gad.348320.121</pub-id><pub-id pub-id-type="pmid">34168039</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>WM</given-names></name><name><surname>Chionh</surname><given-names>YH</given-names></name><name><surname>Hia</surname><given-names>F</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Kellner</surname><given-names>S</given-names></name><name><surname>McBee</surname><given-names>ME</given-names></name><name><surname>Ng</surname><given-names>CS</given-names></name><name><surname>Pang</surname><given-names>YLJ</given-names></name><name><surname>Prestwich</surname><given-names>EG</given-names></name><name><surname>Lim</surname><given-names>KS</given-names></name><name><surname>Babu</surname><given-names>IR</given-names></name><name><surname>Begley</surname><given-names>TJ</given-names></name><name><surname>Dedon</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A platform for discovery and quantification of modified ribonucleosides in rna: application to stress-induced reprogramming of trna modifications</article-title><source>Methods in Enzymology</source><volume>560</volume><fpage>29</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2015.03.004</pub-id><pub-id pub-id-type="pmid">26253965</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>P</given-names></name><name><surname>Dedon</surname><given-names>PC</given-names></name><name><surname>Begley</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lifestyle modifications: coordinating the tRNA epitranscriptome with codon bias to adapt translation during stress responses</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>228</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1611-1</pub-id><pub-id pub-id-type="pmid">30587213</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases</article-title><source>The FEBS Journal</source><volume>288</volume><fpage>5089</fpage><lpage>5121</lpage><pub-id pub-id-type="doi">10.1111/febs.15696</pub-id><pub-id pub-id-type="pmid">33400393</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordes</surname><given-names>M</given-names></name><name><surname>Hierholzer</surname><given-names>J</given-names></name><name><surname>Schelosky</surname><given-names>L</given-names></name><name><surname>Schrag</surname><given-names>A</given-names></name><name><surname>Richter</surname><given-names>WS</given-names></name><name><surname>Eichstädt</surname><given-names>H</given-names></name><name><surname>Schulze</surname><given-names>PE</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Felix</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Iodine-123-iodo-lisuride SPECT in Parkinson’s disease</article-title><source>Journal of Nuclear Medicine</source><volume>37</volume><fpage>22</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">8543995</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewe</surname><given-names>JM</given-names></name><name><surname>Fuller</surname><given-names>BL</given-names></name><name><surname>Lentini</surname><given-names>JM</given-names></name><name><surname>Kellner</surname><given-names>SM</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TRMT1-Catalyzed tRNA modifications are required for redox homeostasis to ensure proper cellular proliferation and oxidative stress survival</article-title><source>Molecular and Cellular Biology</source><volume>37</volume><elocation-id>e00214-17</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00214-17</pub-id><pub-id pub-id-type="pmid">28784718</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Giorgio</surname><given-names>S</given-names></name><name><surname>Martignano</surname><given-names>F</given-names></name><name><surname>Torcia</surname><given-names>MG</given-names></name><name><surname>Mattiuz</surname><given-names>G</given-names></name><name><surname>Conticello</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eabb5813</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abb5813</pub-id><pub-id pub-id-type="pmid">32596474</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>D Oliviera</surname><given-names>A</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Mottaghinia</surname><given-names>S</given-names></name><name><surname>Geissler</surname><given-names>EP</given-names></name><name><surname>Etienne</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Mugridge</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Recognition and Cleavage of Human tRNA Methyltransferase TRMT1 by the SARS-CoV-2 Main Protease</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.02.20.529306</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dremel</surname><given-names>SE</given-names></name><name><surname>Sivrich</surname><given-names>FL</given-names></name><name><surname>Tucker</surname><given-names>JM</given-names></name><name><surname>Glaunsinger</surname><given-names>BA</given-names></name><name><surname>DeLuca</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Manipulation of rna polymerase iii by herpes simplex virus-1</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>623</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28144-8</pub-id><pub-id pub-id-type="pmid">35110532</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dremel</surname><given-names>SE</given-names></name><name><surname>Jimenez</surname><given-names>AR</given-names></name><name><surname>Tucker</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>“Transfer” of power: the intersection of DNA virus infection and tRNA biology</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>146</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2023.01.011</pub-id><pub-id pub-id-type="pmid">36682929</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finkel</surname><given-names>Y</given-names></name><name><surname>Gluck</surname><given-names>A</given-names></name><name><surname>Nachshon</surname><given-names>A</given-names></name><name><surname>Winkler</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>T</given-names></name><name><surname>Rozman</surname><given-names>B</given-names></name><name><surname>Mizrahi</surname><given-names>O</given-names></name><name><surname>Lubelsky</surname><given-names>Y</given-names></name><name><surname>Zuckerman</surname><given-names>B</given-names></name><name><surname>Slobodin</surname><given-names>B</given-names></name><name><surname>Yahalom-Ronen</surname><given-names>Y</given-names></name><name><surname>Tamir</surname><given-names>H</given-names></name><name><surname>Ulitsky</surname><given-names>I</given-names></name><name><surname>Israely</surname><given-names>T</given-names></name><name><surname>Paran</surname><given-names>N</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Stern-Ginossar</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis</article-title><source>Nature</source><volume>594</volume><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03610-3</pub-id><pub-id pub-id-type="pmid">33979833</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Brophy</surname><given-names>JAN</given-names></name><name><surname>Chan</surname><given-names>CTY</given-names></name><name><surname>Atmore</surname><given-names>KA</given-names></name><name><surname>Begley</surname><given-names>U</given-names></name><name><surname>Paules</surname><given-names>RS</given-names></name><name><surname>Dedon</surname><given-names>PC</given-names></name><name><surname>Begley</surname><given-names>TJ</given-names></name><name><surname>Samson</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human AlkB homolog ABH8 Is a tRNA methyltransferase required for wobble uridine modification and DNA damage survival</article-title><source>Molecular and Cellular Biology</source><volume>30</volume><fpage>2449</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1128/MCB.01604-09</pub-id><pub-id pub-id-type="pmid">20308323</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DE</given-names></name><name><surname>Hiatt</surname><given-names>J</given-names></name><name><surname>Bouhaddou</surname><given-names>M</given-names></name><name><surname>Rezelj</surname><given-names>VV</given-names></name><name><surname>Ulferts</surname><given-names>S</given-names></name><name><surname>Braberg</surname><given-names>H</given-names></name><name><surname>Jureka</surname><given-names>AS</given-names></name><name><surname>Obernier</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>JZ</given-names></name><name><surname>Batra</surname><given-names>J</given-names></name><name><surname>Kaake</surname><given-names>RM</given-names></name><name><surname>Weckstein</surname><given-names>AR</given-names></name><name><surname>Owens</surname><given-names>TW</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Pourmal</surname><given-names>S</given-names></name><name><surname>Titus</surname><given-names>EW</given-names></name><name><surname>Cakir</surname><given-names>M</given-names></name><name><surname>Soucheray</surname><given-names>M</given-names></name><name><surname>McGregor</surname><given-names>M</given-names></name><name><surname>Cakir</surname><given-names>Z</given-names></name><name><surname>Jang</surname><given-names>G</given-names></name><name><surname>O’Meara</surname><given-names>MJ</given-names></name><name><surname>Tummino</surname><given-names>TA</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Foussard</surname><given-names>H</given-names></name><name><surname>Rojc</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Kuchenov</surname><given-names>D</given-names></name><name><surname>Hüttenhain</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Eckhardt</surname><given-names>M</given-names></name><name><surname>Swaney</surname><given-names>DL</given-names></name><name><surname>Fabius</surname><given-names>JM</given-names></name><name><surname>Ummadi</surname><given-names>M</given-names></name><name><surname>Tutuncuoglu</surname><given-names>B</given-names></name><name><surname>Rathore</surname><given-names>U</given-names></name><name><surname>Modak</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>P</given-names></name><name><surname>Haas</surname><given-names>KM</given-names></name><name><surname>Naing</surname><given-names>ZZC</given-names></name><name><surname>Pulido</surname><given-names>EH</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Barrio-Hernandez</surname><given-names>I</given-names></name><name><surname>Memon</surname><given-names>D</given-names></name><name><surname>Petsalaki</surname><given-names>E</given-names></name><name><surname>Dunham</surname><given-names>A</given-names></name><name><surname>Marrero</surname><given-names>MC</given-names></name><name><surname>Burke</surname><given-names>D</given-names></name><name><surname>Koh</surname><given-names>C</given-names></name><name><surname>Vallet</surname><given-names>T</given-names></name><name><surname>Silvas</surname><given-names>JA</given-names></name><name><surname>Azumaya</surname><given-names>CM</given-names></name><name><surname>Billesbølle</surname><given-names>C</given-names></name><name><surname>Brilot</surname><given-names>AF</given-names></name><name><surname>Campbell</surname><given-names>MG</given-names></name><name><surname>Diallo</surname><given-names>A</given-names></name><name><surname>Dickinson</surname><given-names>MS</given-names></name><name><surname>Diwanji</surname><given-names>D</given-names></name><name><surname>Herrera</surname><given-names>N</given-names></name><name><surname>Hoppe</surname><given-names>N</given-names></name><name><surname>Kratochvil</surname><given-names>HT</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Merz</surname><given-names>GE</given-names></name><name><surname>Moritz</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>HC</given-names></name><name><surname>Nowotny</surname><given-names>C</given-names></name><name><surname>Puchades</surname><given-names>C</given-names></name><name><surname>Rizo</surname><given-names>AN</given-names></name><name><surname>Schulze-Gahmen</surname><given-names>U</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>ID</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Asarnow</surname><given-names>D</given-names></name><name><surname>Biel</surname><given-names>J</given-names></name><name><surname>Bowen</surname><given-names>A</given-names></name><name><surname>Braxton</surname><given-names>JR</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chio</surname><given-names>CM</given-names></name><name><surname>Chio</surname><given-names>US</given-names></name><name><surname>Deshpande</surname><given-names>I</given-names></name><name><surname>Doan</surname><given-names>L</given-names></name><name><surname>Faust</surname><given-names>B</given-names></name><name><surname>Flores</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Lam</surname><given-names>VL</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lo</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>KE</given-names></name><name><surname>Melo</surname><given-names>AA</given-names></name><name><surname>Moss</surname><given-names>FR</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Paulino</surname><given-names>J</given-names></name><name><surname>Pawar</surname><given-names>KI</given-names></name><name><surname>Peters</surname><given-names>JK</given-names></name><name><surname>Pospiech</surname><given-names>TH</given-names></name><name><surname>Safari</surname><given-names>M</given-names></name><name><surname>Sangwan</surname><given-names>S</given-names></name><name><surname>Schaefer</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>PV</given-names></name><name><surname>Thwin</surname><given-names>AC</given-names></name><name><surname>Trenker</surname><given-names>R</given-names></name><name><surname>Tse</surname><given-names>E</given-names></name><name><surname>Tsui</surname><given-names>TKM</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Whitis</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Saltzberg</surname><given-names>D</given-names></name><name><surname>Hodder</surname><given-names>AJ</given-names></name><name><surname>Shun-Shion</surname><given-names>AS</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>White</surname><given-names>KM</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name><name><surname>Kehrer</surname><given-names>T</given-names></name><name><surname>Miorin</surname><given-names>L</given-names></name><name><surname>Moreno</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>AH</given-names></name><name><surname>Rihn</surname><given-names>S</given-names></name><name><surname>Khalid</surname><given-names>MM</given-names></name><name><surname>Vallejo-Gracia</surname><given-names>A</given-names></name><name><surname>Fozouni</surname><given-names>P</given-names></name><name><surname>Simoneau</surname><given-names>CR</given-names></name><name><surname>Roth</surname><given-names>TL</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Karim</surname><given-names>MA</given-names></name><name><surname>Ghoussaini</surname><given-names>M</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Berardi</surname><given-names>F</given-names></name><name><surname>Weigang</surname><given-names>S</given-names></name><name><surname>Chazal</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Logue</surname><given-names>J</given-names></name><name><surname>McGrath</surname><given-names>M</given-names></name><name><surname>Weston</surname><given-names>S</given-names></name><name><surname>Haupt</surname><given-names>R</given-names></name><name><surname>Hastie</surname><given-names>CJ</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>F</given-names></name><name><surname>Burness</surname><given-names>KA</given-names></name><name><surname>Reid</surname><given-names>E</given-names></name><name><surname>Dorward</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Wilkinson</surname><given-names>SG</given-names></name><name><surname>Geyer</surname><given-names>A</given-names></name><name><surname>Giesel</surname><given-names>DM</given-names></name><name><surname>Baillie</surname><given-names>C</given-names></name><name><surname>Raggett</surname><given-names>S</given-names></name><name><surname>Leech</surname><given-names>H</given-names></name><name><surname>Toth</surname><given-names>R</given-names></name><name><surname>Goodman</surname><given-names>N</given-names></name><name><surname>Keough</surname><given-names>KC</given-names></name><name><surname>Lind</surname><given-names>AL</given-names></name><name><surname>Klesh</surname><given-names>RJ</given-names></name><name><surname>Hemphill</surname><given-names>KR</given-names></name><name><surname>Carlson-Stevermer</surname><given-names>J</given-names></name><name><surname>Oki</surname><given-names>J</given-names></name><name><surname>Holden</surname><given-names>K</given-names></name><name><surname>Maures</surname><given-names>T</given-names></name><name><surname>Pollard</surname><given-names>KS</given-names></name><name><surname>Sali</surname><given-names>A</given-names></name><name><surname>Agard</surname><given-names>DA</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name><name><surname>Jura</surname><given-names>N</given-names></name><name><surname>Kortemme</surname><given-names>T</given-names></name><name><surname>Manglik</surname><given-names>A</given-names></name><name><surname>Southworth</surname><given-names>DR</given-names></name><name><surname>Stroud</surname><given-names>RM</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name><name><surname>Abate</surname><given-names>C</given-names></name><name><surname>Jouvenet</surname><given-names>N</given-names></name><name><surname>Kochs</surname><given-names>G</given-names></name><name><surname>Shoichet</surname><given-names>B</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name><name><surname>Palmarini</surname><given-names>M</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name><name><surname>Rassen</surname><given-names>JA</given-names></name><name><surname>Grosse</surname><given-names>R</given-names></name><name><surname>Rosenberg</surname><given-names>OS</given-names></name><name><surname>Verba</surname><given-names>KA</given-names></name><name><surname>Basler</surname><given-names>CF</given-names></name><name><surname>Vignuzzi</surname><given-names>M</given-names></name><name><surname>Peden</surname><given-names>AA</given-names></name><name><surname>Beltrao</surname><given-names>P</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><collab>QCRG Structural Biology Consortium</collab><collab>Zoonomia Consortium</collab></person-group><year iso-8601-date="2020">2020a</year><article-title>Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms</article-title><source>Science</source><volume>370</volume><elocation-id>eabe9403</elocation-id><pub-id pub-id-type="doi">10.1126/science.abe9403</pub-id><pub-id pub-id-type="pmid">33060197</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DE</given-names></name><name><surname>Jang</surname><given-names>GM</given-names></name><name><surname>Bouhaddou</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Obernier</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>KM</given-names></name><name><surname>O’Meara</surname><given-names>MJ</given-names></name><name><surname>Rezelj</surname><given-names>VV</given-names></name><name><surname>Guo</surname><given-names>JZ</given-names></name><name><surname>Swaney</surname><given-names>DL</given-names></name><name><surname>Tummino</surname><given-names>TA</given-names></name><name><surname>Hüttenhain</surname><given-names>R</given-names></name><name><surname>Kaake</surname><given-names>RM</given-names></name><name><surname>Richards</surname><given-names>AL</given-names></name><name><surname>Tutuncuoglu</surname><given-names>B</given-names></name><name><surname>Foussard</surname><given-names>H</given-names></name><name><surname>Batra</surname><given-names>J</given-names></name><name><surname>Haas</surname><given-names>K</given-names></name><name><surname>Modak</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>P</given-names></name><name><surname>Polacco</surname><given-names>BJ</given-names></name><name><surname>Braberg</surname><given-names>H</given-names></name><name><surname>Fabius</surname><given-names>JM</given-names></name><name><surname>Eckhardt</surname><given-names>M</given-names></name><name><surname>Soucheray</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>MJ</given-names></name><name><surname>Cakir</surname><given-names>M</given-names></name><name><surname>McGregor</surname><given-names>MJ</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Meyer</surname><given-names>B</given-names></name><name><surname>Roesch</surname><given-names>F</given-names></name><name><surname>Vallet</surname><given-names>T</given-names></name><name><surname>Mac Kain</surname><given-names>A</given-names></name><name><surname>Miorin</surname><given-names>L</given-names></name><name><surname>Moreno</surname><given-names>E</given-names></name><name><surname>Naing</surname><given-names>ZZC</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Kirby</surname><given-names>IT</given-names></name><name><surname>Melnyk</surname><given-names>JE</given-names></name><name><surname>Chorba</surname><given-names>JS</given-names></name><name><surname>Lou</surname><given-names>K</given-names></name><name><surname>Dai</surname><given-names>SA</given-names></name><name><surname>Barrio-Hernandez</surname><given-names>I</given-names></name><name><surname>Memon</surname><given-names>D</given-names></name><name><surname>Hernandez-Armenta</surname><given-names>C</given-names></name><name><surname>Lyu</surname><given-names>J</given-names></name><name><surname>Mathy</surname><given-names>CJP</given-names></name><name><surname>Perica</surname><given-names>T</given-names></name><name><surname>Pilla</surname><given-names>KB</given-names></name><name><surname>Ganesan</surname><given-names>SJ</given-names></name><name><surname>Saltzberg</surname><given-names>DJ</given-names></name><name><surname>Rakesh</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Rosenthal</surname><given-names>SB</given-names></name><name><surname>Calviello</surname><given-names>L</given-names></name><name><surname>Venkataramanan</surname><given-names>S</given-names></name><name><surname>Liboy-Lugo</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>XP</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wankowicz</surname><given-names>SA</given-names></name><name><surname>Bohn</surname><given-names>M</given-names></name><name><surname>Safari</surname><given-names>M</given-names></name><name><surname>Ugur</surname><given-names>FS</given-names></name><name><surname>Koh</surname><given-names>C</given-names></name><name><surname>Savar</surname><given-names>NS</given-names></name><name><surname>Tran</surname><given-names>QD</given-names></name><name><surname>Shengjuler</surname><given-names>D</given-names></name><name><surname>Fletcher</surname><given-names>SJ</given-names></name><name><surname>O’Neal</surname><given-names>MC</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>JCJ</given-names></name><name><surname>Broadhurst</surname><given-names>DJ</given-names></name><name><surname>Klippsten</surname><given-names>S</given-names></name><name><surname>Sharp</surname><given-names>PP</given-names></name><name><surname>Wenzell</surname><given-names>NA</given-names></name><name><surname>Kuzuoglu-Ozturk</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Trenker</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>JM</given-names></name><name><surname>Cavero</surname><given-names>DA</given-names></name><name><surname>Hiatt</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>TL</given-names></name><name><surname>Rathore</surname><given-names>U</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Noack</surname><given-names>J</given-names></name><name><surname>Hubert</surname><given-names>M</given-names></name><name><surname>Stroud</surname><given-names>RM</given-names></name><name><surname>Frankel</surname><given-names>AD</given-names></name><name><surname>Rosenberg</surname><given-names>OS</given-names></name><name><surname>Verba</surname><given-names>KA</given-names></name><name><surname>Agard</surname><given-names>DA</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Jura</surname><given-names>N</given-names></name><name><surname>von Zastrow</surname><given-names>M</given-names></name><name><surname>Verdin</surname><given-names>E</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>d’Enfert</surname><given-names>C</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Jacobson</surname><given-names>M</given-names></name><name><surname>Malik</surname><given-names>HS</given-names></name><name><surname>Fujimori</surname><given-names>DG</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name><name><surname>Craik</surname><given-names>CS</given-names></name><name><surname>Floor</surname><given-names>SN</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name><name><surname>Gross</surname><given-names>JD</given-names></name><name><surname>Sali</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name><name><surname>Taunton</surname><given-names>J</given-names></name><name><surname>Kortemme</surname><given-names>T</given-names></name><name><surname>Beltrao</surname><given-names>P</given-names></name><name><surname>Vignuzzi</surname><given-names>M</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Shoichet</surname><given-names>BK</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title><source>Nature</source><volume>583</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id><pub-id pub-id-type="pmid">32353859</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grum-Tokars</surname><given-names>V</given-names></name><name><surname>Ratia</surname><given-names>K</given-names></name><name><surname>Begaye</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Mesecar</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery</article-title><source>Virus Research</source><volume>133</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2007.02.015</pub-id><pub-id pub-id-type="pmid">17397958</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartenian</surname><given-names>E</given-names></name><name><surname>Nandakumar</surname><given-names>D</given-names></name><name><surname>Lari</surname><given-names>A</given-names></name><name><surname>Ly</surname><given-names>M</given-names></name><name><surname>Tucker</surname><given-names>JM</given-names></name><name><surname>Glaunsinger</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The molecular virology of coronaviruses</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>12910</fpage><lpage>12934</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV120.013930</pub-id><pub-id pub-id-type="pmid">32661197</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilmann</surname><given-names>E</given-names></name><name><surname>Costacurta</surname><given-names>F</given-names></name><name><surname>Geley</surname><given-names>S</given-names></name><name><surname>Mogadashi</surname><given-names>SA</given-names></name><name><surname>Volland</surname><given-names>A</given-names></name><name><surname>Rupp</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>von Laer</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>391</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03277-0</pub-id><pub-id pub-id-type="pmid">35478219</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Alias</surname><given-names>X</given-names></name><name><surname>Benisty</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>MH</given-names></name><name><surname>Serrano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Translational adaptation of human viruses to the tissues they infect</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108872</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108872</pub-id><pub-id pub-id-type="pmid">33730572</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Musier-Forsyth</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of host tRNAs and aminoacyl-tRNA synthetases in retroviral replication</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>5352</fpage><lpage>5364</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV118.002957</pub-id><pub-id pub-id-type="pmid">30700559</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Ouyang</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Zhuang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Duan</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genome-wide analysis of the indispensable role of non-structural proteins in the replication of sars-cov-2</article-title><source>Frontiers in Microbiology</source><volume>13</volume><elocation-id>907422</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.907422</pub-id><pub-id pub-id-type="pmid">35722274</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonkhout</surname><given-names>N</given-names></name><name><surname>Cruciani</surname><given-names>S</given-names></name><name><surname>Santos Vieira</surname><given-names>HG</given-names></name><name><surname>Tran</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Pickford</surname><given-names>R</given-names></name><name><surname>Kaczorowski</surname><given-names>D</given-names></name><name><surname>Franco</surname><given-names>GR</given-names></name><name><surname>Vauti</surname><given-names>F</given-names></name><name><surname>Camacho</surname><given-names>N</given-names></name><name><surname>Abedini</surname><given-names>SS</given-names></name><name><surname>Najmabadi</surname><given-names>H</given-names></name><name><surname>Ribas de Pouplana</surname><given-names>L</given-names></name><name><surname>Christ</surname><given-names>D</given-names></name><name><surname>Schonrock</surname><given-names>N</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name><name><surname>Novoa</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Subcellular relocalization and nuclear redistribution of the RNA methyltransferases TRMT1 and TRMT1L upon neuronal activation</article-title><source>RNA Biology</source><volume>18</volume><fpage>1905</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.1080/15476286.2021.1881291</pub-id><pub-id pub-id-type="pmid">33499731</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungfleisch</surname><given-names>J</given-names></name><name><surname>Böttcher</surname><given-names>R</given-names></name><name><surname>Talló-Parra</surname><given-names>M</given-names></name><name><surname>Pérez-Vilaró</surname><given-names>G</given-names></name><name><surname>Merits</surname><given-names>A</given-names></name><name><surname>Novoa</surname><given-names>EM</given-names></name><name><surname>Díez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CHIKV infection reprograms codon optimality to favor viral RNA translation by altering the tRNA epitranscriptome</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>4725</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31835-x</pub-id><pub-id pub-id-type="pmid">35953468</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamitani</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Narayanan</surname><given-names>K</given-names></name><name><surname>Lokugamage</surname><given-names>KG</given-names></name><name><surname>Makino</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>16</volume><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1680</pub-id><pub-id pub-id-type="pmid">19838190</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katanski</surname><given-names>CD</given-names></name><name><surname>Alshammary</surname><given-names>H</given-names></name><name><surname>Watkins</surname><given-names>CP</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Gonzales-Reiche</surname><given-names>A</given-names></name><name><surname>Sordillo</surname><given-names>EM</given-names></name><name><surname>van Bakel</surname><given-names>H</given-names></name><collab>Mount Sinai PSP study group</collab><name><surname>Lolans</surname><given-names>K</given-names></name><name><surname>Simon</surname><given-names>V</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>tRNA abundance, modification and fragmentation in nasopharyngeal swabs as biomarkers for COVID-19 severity</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>999351</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.999351</pub-id><pub-id pub-id-type="pmid">36393870</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>VN</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The architecture of SARS-CoV-2 transcriptome</article-title><source>Cell</source><volume>181</volume><fpage>914</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.011</pub-id><pub-id pub-id-type="pmid">32330414</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 pathogenesis</article-title><source>Nature Reviews. Microbiology</source><volume>20</volume><fpage>270</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00713-0</pub-id><pub-id pub-id-type="pmid">35354968</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapointe</surname><given-names>CP</given-names></name><name><surname>Grosely</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>AG</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fernández</surname><given-names>IS</given-names></name><name><surname>Puglisi</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2017715118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2017715118</pub-id><pub-id pub-id-type="pmid">33479166</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Worrall</surname><given-names>LJ</given-names></name><name><surname>Vuckovic</surname><given-names>M</given-names></name><name><surname>Rosell</surname><given-names>FI</given-names></name><name><surname>Gentile</surname><given-names>F</given-names></name><name><surname>Ton</surname><given-names>AT</given-names></name><name><surname>Caveney</surname><given-names>NA</given-names></name><name><surname>Ban</surname><given-names>F</given-names></name><name><surname>Cherkasov</surname><given-names>A</given-names></name><name><surname>Paetzel</surname><given-names>M</given-names></name><name><surname>Strynadka</surname><given-names>NCJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5877</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19662-4</pub-id><pub-id pub-id-type="pmid">33208735</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kenward</surname><given-names>C</given-names></name><name><surname>Worrall</surname><given-names>LJ</given-names></name><name><surname>Vuckovic</surname><given-names>M</given-names></name><name><surname>Gentile</surname><given-names>F</given-names></name><name><surname>Ton</surname><given-names>AT</given-names></name><name><surname>Ng</surname><given-names>M</given-names></name><name><surname>Cherkasov</surname><given-names>A</given-names></name><name><surname>Strynadka</surname><given-names>NCJ</given-names></name><name><surname>Paetzel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5196</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-32854-4</pub-id><pub-id pub-id-type="pmid">36057636</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentini</surname><given-names>JM</given-names></name><name><surname>Alsaif</surname><given-names>HS</given-names></name><name><surname>Faqeih</surname><given-names>E</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DALRD3 encodes a protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine modification</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2510</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16321-6</pub-id><pub-id pub-id-type="pmid">32427860</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentini</surname><given-names>JM</given-names></name><name><surname>Bargabos</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Methyltransferase METTL8 is required for 3-methylcytosine modification in human mitochondrial tRNAs</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>101788</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101788</pub-id><pub-id pub-id-type="pmid">35247384</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesiewicz</surname><given-names>J</given-names></name><name><surname>Dudock</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>In vitro methylation of tobacco mosaic virus RNA with ribothymidine-forming tRNA methyltransferase. Characterization and specificity of the reaction</article-title><source>Biochimica et Biophysica Acta</source><volume>520</volume><fpage>411</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/0005-2787(78)90238-1</pub-id><pub-id pub-id-type="pmid">361090</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>H</given-names></name><name><surname>Bray</surname><given-names>B</given-names></name><name><surname>Gonzalez</surname><given-names>GM</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>KG</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Carlin</surname><given-names>AF</given-names></name><name><surname>Rana</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection</article-title><source>Cell Reports</source><volume>35</volume><elocation-id>109091</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109091</pub-id><pub-id pub-id-type="pmid">33961823</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>KDELC1 and TRMT1 serve as prognosis-related sars-cov-2 proteins binding human mrnas and promising biomarkers in clear cell renal cell carcinoma</article-title><source>International Journal of General Medicine</source><volume>14</volume><fpage>2475</fpage><lpage>2490</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S312416</pub-id><pub-id pub-id-type="pmid">34163216</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Ngo</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>JJ</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>TY</given-names></name><name><surname>Carriere</surname><given-names>J</given-names></name><name><surname>Savas</surname><given-names>AC</given-names></name><name><surname>Zarinfar</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Camarero</surname><given-names>JA</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>XS</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting rig-i and mavs to evade the innate immune response</article-title><source>mBio</source><volume>12</volume><elocation-id>e0233521</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02335-21</pub-id><pub-id pub-id-type="pmid">34544279</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>JL</given-names></name><name><surname>Zhou</surname><given-names>XL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 main protease Nsp5 cleaves and inactivates human tRNA methyltransferase TRMT1</article-title><source>Journal of Molecular Cell Biology</source><volume>15</volume><elocation-id>mjad024</elocation-id><pub-id pub-id-type="doi">10.1093/jmcb/mjad024</pub-id><pub-id pub-id-type="pmid">37073102</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Blish</surname><given-names>CA</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The immunology and immunopathology of COVID-19</article-title><source>Science</source><volume>375</volume><fpage>1122</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1126/science.abm8108</pub-id><pub-id pub-id-type="pmid">35271343</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>B</given-names></name><name><surname>Chiaravalli</surname><given-names>J</given-names></name><name><surname>Gellenoncourt</surname><given-names>S</given-names></name><name><surname>Brownridge</surname><given-names>P</given-names></name><name><surname>Bryne</surname><given-names>DP</given-names></name><name><surname>Daly</surname><given-names>LA</given-names></name><name><surname>Grauslys</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>M</given-names></name><name><surname>Agou</surname><given-names>F</given-names></name><name><surname>Chakrabarti</surname><given-names>LA</given-names></name><name><surname>Craik</surname><given-names>CS</given-names></name><name><surname>Eyers</surname><given-names>CE</given-names></name><name><surname>Eyers</surname><given-names>PA</given-names></name><name><surname>Gambin</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Sierecki</surname><given-names>E</given-names></name><name><surname>Verdin</surname><given-names>E</given-names></name><name><surname>Vignuzzi</surname><given-names>M</given-names></name><name><surname>Emmott</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>5553</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-25796-w</pub-id><pub-id pub-id-type="pmid">34548480</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>JM</given-names></name><name><surname>Ramanathan</surname><given-names>M</given-names></name><name><surname>Shanderson</surname><given-names>RL</given-names></name><name><surname>Beck</surname><given-names>A</given-names></name><name><surname>Donohue</surname><given-names>L</given-names></name><name><surname>Ferguson</surname><given-names>I</given-names></name><name><surname>Guo</surname><given-names>MG</given-names></name><name><surname>Rao</surname><given-names>DS</given-names></name><name><surname>Miao</surname><given-names>W</given-names></name><name><surname>Reynolds</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>YY</given-names></name><name><surname>Blish</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Khavari</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The proximal proteome of 17 SARS-CoV-2 proteins links to disrupted antiviral signaling and host translation</article-title><source>PLOS Pathogens</source><volume>17</volume><elocation-id>e1009412</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009412</pub-id><pub-id pub-id-type="pmid">34597346</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minkoff</surname><given-names>JM</given-names></name><name><surname>tenOever</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Innate immune evasion strategies of SARS-CoV-2</article-title><source>Nature Reviews. Microbiology</source><volume>21</volume><fpage>178</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00839-1</pub-id><pub-id pub-id-type="pmid">36631691</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moustaqil</surname><given-names>M</given-names></name><name><surname>Ollivier</surname><given-names>E</given-names></name><name><surname>Chiu</surname><given-names>HP</given-names></name><name><surname>Van Tol</surname><given-names>S</given-names></name><name><surname>Rudolffi-Soto</surname><given-names>P</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Bhumkar</surname><given-names>A</given-names></name><name><surname>Hunter</surname><given-names>DJB</given-names></name><name><surname>Freiberg</surname><given-names>AN</given-names></name><name><surname>Jacques</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Sierecki</surname><given-names>E</given-names></name><name><surname>Gambin</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species</article-title><source>Emerging Microbes &amp; Infections</source><volume>10</volume><fpage>178</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1870414</pub-id><pub-id pub-id-type="pmid">33372854</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><name><surname>Nishii</surname><given-names>W</given-names></name><name><surname>Terada</surname><given-names>T</given-names></name><name><surname>Shirouzu</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C-like protease (SARS-CoV 3CLpro) from its polyproteins</article-title><source>The FEBS Journal</source><volume>280</volume><fpage>2002</fpage><lpage>2013</lpage><pub-id pub-id-type="doi">10.1111/febs.12222</pub-id><pub-id pub-id-type="pmid">23452147</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najmabadi</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Garshasbi</surname><given-names>M</given-names></name><name><surname>Zemojtel</surname><given-names>T</given-names></name><name><surname>Abedini</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Hosseini</surname><given-names>M</given-names></name><name><surname>Behjati</surname><given-names>F</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Jamali</surname><given-names>P</given-names></name><name><surname>Zecha</surname><given-names>A</given-names></name><name><surname>Mohseni</surname><given-names>M</given-names></name><name><surname>Püttmann</surname><given-names>L</given-names></name><name><surname>Vahid</surname><given-names>LN</given-names></name><name><surname>Jensen</surname><given-names>C</given-names></name><name><surname>Moheb</surname><given-names>LA</given-names></name><name><surname>Bienek</surname><given-names>M</given-names></name><name><surname>Larti</surname><given-names>F</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Weissmann</surname><given-names>R</given-names></name><name><surname>Darvish</surname><given-names>H</given-names></name><name><surname>Wrogemann</surname><given-names>K</given-names></name><name><surname>Hadavi</surname><given-names>V</given-names></name><name><surname>Lipkowitz</surname><given-names>B</given-names></name><name><surname>Esmaeeli-Nieh</surname><given-names>S</given-names></name><name><surname>Wieczorek</surname><given-names>D</given-names></name><name><surname>Kariminejad</surname><given-names>R</given-names></name><name><surname>Firouzabadi</surname><given-names>SG</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Fattahi</surname><given-names>Z</given-names></name><name><surname>Rost</surname><given-names>I</given-names></name><name><surname>Mojahedi</surname><given-names>F</given-names></name><name><surname>Hertzberg</surname><given-names>C</given-names></name><name><surname>Dehghan</surname><given-names>A</given-names></name><name><surname>Rajab</surname><given-names>A</given-names></name><name><surname>Banavandi</surname><given-names>MJS</given-names></name><name><surname>Hoffer</surname><given-names>J</given-names></name><name><surname>Falah</surname><given-names>M</given-names></name><name><surname>Musante</surname><given-names>L</given-names></name><name><surname>Kalscheuer</surname><given-names>V</given-names></name><name><surname>Ullmann</surname><given-names>R</given-names></name><name><surname>Kuss</surname><given-names>AW</given-names></name><name><surname>Tzschach</surname><given-names>A</given-names></name><name><surname>Kahrizi</surname><given-names>K</given-names></name><name><surname>Ropers</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Deep sequencing reveals 50 novel genes for recessive cognitive disorders</article-title><source>Nature</source><volume>478</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nature10423</pub-id><pub-id pub-id-type="pmid">21937992</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>A</given-names></name><name><surname>Toner</surname><given-names>SA</given-names></name><name><surname>Jose</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases</article-title><source>Biochemical Society Transactions</source><volume>50</volume><fpage>151</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1042/BST20211180</pub-id><pub-id pub-id-type="pmid">35015073</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netzer</surname><given-names>N</given-names></name><name><surname>Goodenbour</surname><given-names>JM</given-names></name><name><surname>David</surname><given-names>A</given-names></name><name><surname>Dittmar</surname><given-names>KA</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name><name><surname>Schneider</surname><given-names>JR</given-names></name><name><surname>Boone</surname><given-names>D</given-names></name><name><surname>Eves</surname><given-names>EM</given-names></name><name><surname>Rosner</surname><given-names>MR</given-names></name><name><surname>Gibbs</surname><given-names>JS</given-names></name><name><surname>Embry</surname><given-names>A</given-names></name><name><surname>Dolan</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Hickman</surname><given-names>HD</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Bennink</surname><given-names>JR</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Innate immune and chemically triggered oxidative stress modifies translational fidelity</article-title><source>Nature</source><volume>462</volume><fpage>522</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/nature08576</pub-id><pub-id pub-id-type="pmid">19940929</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Yue</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>Lyu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multi-organ proteomic landscape of COVID-19 autopsies</article-title><source>Cell</source><volume>184</volume><fpage>775</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.004</pub-id><pub-id pub-id-type="pmid">33503446</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>A</given-names></name><name><surname>Ribeiro</surname><given-names>DR</given-names></name><name><surname>Marques</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>MAS</given-names></name><name><surname>Ribeiro</surname><given-names>D</given-names></name><name><surname>Soares</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Emerging roles of tRNAs in RNA virus infections</article-title><source>Trends in Biochemical Sciences</source><volume>45</volume><fpage>794</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2020.05.007</pub-id><pub-id pub-id-type="pmid">32505636</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>DR</given-names></name><name><surname>Allerton</surname><given-names>CMN</given-names></name><name><surname>Anderson</surname><given-names>AS</given-names></name><name><surname>Aschenbrenner</surname><given-names>L</given-names></name><name><surname>Avery</surname><given-names>M</given-names></name><name><surname>Berritt</surname><given-names>S</given-names></name><name><surname>Boras</surname><given-names>B</given-names></name><name><surname>Cardin</surname><given-names>RD</given-names></name><name><surname>Carlo</surname><given-names>A</given-names></name><name><surname>Coffman</surname><given-names>KJ</given-names></name><name><surname>Dantonio</surname><given-names>A</given-names></name><name><surname>Di</surname><given-names>L</given-names></name><name><surname>Eng</surname><given-names>H</given-names></name><name><surname>Ferre</surname><given-names>R</given-names></name><name><surname>Gajiwala</surname><given-names>KS</given-names></name><name><surname>Gibson</surname><given-names>SA</given-names></name><name><surname>Greasley</surname><given-names>SE</given-names></name><name><surname>Hurst</surname><given-names>BL</given-names></name><name><surname>Kadar</surname><given-names>EP</given-names></name><name><surname>Kalgutkar</surname><given-names>AS</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Mason</surname><given-names>SW</given-names></name><name><surname>Noell</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>JJ</given-names></name><name><surname>Obach</surname><given-names>RS</given-names></name><name><surname>Ogilvie</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>NC</given-names></name><name><surname>Pettersson</surname><given-names>M</given-names></name><name><surname>Rai</surname><given-names>DK</given-names></name><name><surname>Reese</surname><given-names>MR</given-names></name><name><surname>Sammons</surname><given-names>MF</given-names></name><name><surname>Sathish</surname><given-names>JG</given-names></name><name><surname>Singh</surname><given-names>RSP</given-names></name><name><surname>Steppan</surname><given-names>CM</given-names></name><name><surname>Stewart</surname><given-names>AE</given-names></name><name><surname>Tuttle</surname><given-names>JB</given-names></name><name><surname>Updyke</surname><given-names>L</given-names></name><name><surname>Verhoest</surname><given-names>PR</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19</article-title><source>Science</source><volume>374</volume><fpage>1586</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1126/science.abl4784</pub-id><pub-id pub-id-type="pmid">34726479</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallan</surname><given-names>PS</given-names></name><name><surname>Kreutz</surname><given-names>C</given-names></name><name><surname>Bosio</surname><given-names>S</given-names></name><name><surname>Micura</surname><given-names>R</given-names></name><name><surname>Egli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Effects of N2,N2-dimethylguanosine on RNA structure and stability: crystal structure of an RNA duplex with tandem m2 2G:A pairs</article-title><source>RNA</source><volume>14</volume><fpage>2125</fpage><lpage>2135</lpage><pub-id pub-id-type="doi">10.1261/rna.1078508</pub-id><pub-id pub-id-type="pmid">18772248</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavon-Eternod</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>A</given-names></name><name><surname>Dittmar</surname><given-names>K</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Bennink</surname><given-names>JR</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Vaccinia and influenza A viruses select rather than adjust tRNAs to optimize translation</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>1914</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1093/nar/gks986</pub-id><pub-id pub-id-type="pmid">23254333</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peña</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Watkins</surname><given-names>C</given-names></name><name><surname>Halucha</surname><given-names>M</given-names></name><name><surname>Alshammary</surname><given-names>H</given-names></name><name><surname>Hernandez</surname><given-names>MM</given-names></name><name><surname>Liu</surname><given-names>WC</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>V</given-names></name><name><surname>Katanski</surname><given-names>C</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Profiling selective packaging of host RNA and viral RNA modification in SARS-CoV-2 viral preparations</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>768356</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.768356</pub-id><pub-id pub-id-type="pmid">35186917</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>RNA editing increases the nucleotide diversity of SARS-CoV-2 in human host cells</article-title><source>PLOS Genetics</source><volume>18</volume><elocation-id>e1010130</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1010130</pub-id><pub-id pub-id-type="pmid">35353808</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>M</given-names></name><name><surname>Nance</surname><given-names>KD</given-names></name><name><surname>Bak</surname><given-names>DW</given-names></name><name><surname>Thalalla Gamage</surname><given-names>S</given-names></name><name><surname>Najera</surname><given-names>SS</given-names></name><name><surname>Conte</surname><given-names>AN</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Weerapana</surname><given-names>E</given-names></name><name><surname>Meier</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Conditional covalent lethality driven by oncometabolite accumulation</article-title><source>ACS Chemical Biology</source><volume>17</volume><fpage>2789</fpage><lpage>2800</lpage><pub-id pub-id-type="doi">10.1021/acschembio.2c00384</pub-id><pub-id pub-id-type="pmid">36190452</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hagelskamp</surname><given-names>F</given-names></name><name><surname>Kellner</surname><given-names>SM</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Phizicky</surname><given-names>EM</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Formation of tRNA wobble inosine in humans is disrupted by a millennia-old mutation causing intellectual disability</article-title><source>Molecular and Cellular Biology</source><volume>39</volume><elocation-id>e00203-19</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00203-19</pub-id><pub-id pub-id-type="pmid">31263000</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymonda</surname><given-names>MH</given-names></name><name><surname>Ciesla</surname><given-names>JH</given-names></name><name><surname>Monaghan</surname><given-names>M</given-names></name><name><surname>Leach</surname><given-names>J</given-names></name><name><surname>Asantewaa</surname><given-names>G</given-names></name><name><surname>Smorodintsev-Schiller</surname><given-names>LA</given-names></name><name><surname>Lutz</surname><given-names>MM</given-names></name><name><surname>Schafer</surname><given-names>XL</given-names></name><name><surname>Takimoto</surname><given-names>T</given-names></name><name><surname>Dewhurst</surname><given-names>S</given-names></name><name><surname>Munger</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>IS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro</article-title><source>Virology</source><volume>566</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2021.11.008</pub-id><pub-id pub-id-type="pmid">34871905</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebendenne</surname><given-names>A</given-names></name><name><surname>Valadão</surname><given-names>ALC</given-names></name><name><surname>Tauziet</surname><given-names>M</given-names></name><name><surname>Maarifi</surname><given-names>G</given-names></name><name><surname>Bonaventure</surname><given-names>B</given-names></name><name><surname>McKellar</surname><given-names>J</given-names></name><name><surname>Planès</surname><given-names>R</given-names></name><name><surname>Nisole</surname><given-names>S</given-names></name><name><surname>Arnaud-Arnould</surname><given-names>M</given-names></name><name><surname>Moncorgé</surname><given-names>O</given-names></name><name><surname>Goujon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells</article-title><source>Journal of Virology</source><volume>95</volume><elocation-id>e02415-20</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.02415-20</pub-id><pub-id pub-id-type="pmid">33514628</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resnick</surname><given-names>SJ</given-names></name><name><surname>Iketani</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>SJ</given-names></name><name><surname>Zask</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Melore</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>FY</given-names></name><name><surname>Nair</surname><given-names>MS</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Tay</surname><given-names>NES</given-names></name><name><surname>Rovis</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>HW</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Chavez</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inhibitors of coronavirus 3CL proteases protect cells from protease-mediated cytotoxicity</article-title><source>Journal of Virology</source><volume>95</volume><elocation-id>e0237420</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.02374-20</pub-id><pub-id pub-id-type="pmid">33910954</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Samavarchi-Tehrani</surname><given-names>P</given-names></name><name><surname>Abdouni</surname><given-names>H</given-names></name><name><surname>Knight</surname><given-names>JDR</given-names></name><name><surname>Astori</surname><given-names>A</given-names></name><name><surname>Samson</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>ZY</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Knapp</surname><given-names>JJ</given-names></name><name><surname>St-Germain</surname><given-names>J</given-names></name><name><surname>Go</surname><given-names>CD</given-names></name><name><surname>Larsen</surname><given-names>B</given-names></name><name><surname>Wong</surname><given-names>CJ</given-names></name><name><surname>Cassonnet</surname><given-names>P</given-names></name><name><surname>Demeret</surname><given-names>C</given-names></name><name><surname>Jacob</surname><given-names>Y</given-names></name><name><surname>Roth</surname><given-names>FP</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A SARS-CoV-2 – Host Proximity Interactome</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.09.03.282103</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>TGM</given-names></name><name><surname>Batz</surname><given-names>L</given-names></name><name><surname>Bonet</surname><given-names>L</given-names></name><name><surname>Carl</surname><given-names>U</given-names></name><name><surname>Holzapfel</surname><given-names>G</given-names></name><name><surname>Kiem</surname><given-names>K</given-names></name><name><surname>Matulewicz</surname><given-names>K</given-names></name><name><surname>Niermeier</surname><given-names>D</given-names></name><name><surname>Schuchardt</surname><given-names>I</given-names></name><name><surname>Stanar</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Development of the Twin-Strep-tag and its application for purification of recombinant proteins from cell culture supernatants</article-title><source>Protein Expression and Purification</source><volume>92</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2013.08.021</pub-id><pub-id pub-id-type="pmid">24012791</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>K</given-names></name><name><surname>Karousis</surname><given-names>ED</given-names></name><name><surname>Jomaa</surname><given-names>A</given-names></name><name><surname>Scaiola</surname><given-names>A</given-names></name><name><surname>Echeverria</surname><given-names>B</given-names></name><name><surname>Gurzeler</surname><given-names>L-A</given-names></name><name><surname>Leibundgut</surname><given-names>M</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Mühlemann</surname><given-names>O</given-names></name><name><surname>Ban</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>959</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0511-8</pub-id><pub-id pub-id-type="pmid">32908316</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>S</given-names></name><name><surname>Cedergren</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A correlation between N2-dimethylguanosine presence and alternate tRNA conformers</article-title><source>RNA</source><volume>1</volume><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">8548653</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryawanshi</surname><given-names>RK</given-names></name><name><surname>Koganti</surname><given-names>R</given-names></name><name><surname>Agelidis</surname><given-names>A</given-names></name><name><surname>Patil</surname><given-names>CD</given-names></name><name><surname>Shukla</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dysregulation of cell signaling by SARS-CoV-2</article-title><source>Trends in Microbiology</source><volume>29</volume><fpage>224</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2020.12.007</pub-id><pub-id pub-id-type="pmid">33451855</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoms</surname><given-names>M</given-names></name><name><surname>Buschauer</surname><given-names>R</given-names></name><name><surname>Ameismeier</surname><given-names>M</given-names></name><name><surname>Koepke</surname><given-names>L</given-names></name><name><surname>Denk</surname><given-names>T</given-names></name><name><surname>Hirschenberger</surname><given-names>M</given-names></name><name><surname>Kratzat</surname><given-names>H</given-names></name><name><surname>Hayn</surname><given-names>M</given-names></name><name><surname>Mackens-Kiani</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Straub</surname><given-names>JH</given-names></name><name><surname>Stürzel</surname><given-names>CM</given-names></name><name><surname>Fröhlich</surname><given-names>T</given-names></name><name><surname>Berninghausen</surname><given-names>O</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Sparrer</surname><given-names>KMJ</given-names></name><name><surname>Beckmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2</article-title><source>Science</source><volume>369</volume><fpage>1249</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1126/science.abc8665</pub-id><pub-id pub-id-type="pmid">32680882</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tidu</surname><given-names>A</given-names></name><name><surname>Janvier</surname><given-names>A</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Sosnowski</surname><given-names>P</given-names></name><name><surname>Kuhn</surname><given-names>L</given-names></name><name><surname>Hammann</surname><given-names>P</given-names></name><name><surname>Westhof</surname><given-names>E</given-names></name><name><surname>Eriani</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation</article-title><source>RNA</source><volume>27</volume><fpage>253</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1261/rna.078121.120</pub-id><pub-id pub-id-type="pmid">33268501</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>JM</given-names></name><name><surname>Schaller</surname><given-names>AM</given-names></name><name><surname>Willis</surname><given-names>I</given-names></name><name><surname>Glaunsinger</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alteration of the premature tRNA landscape by gammaherpesvirus infection</article-title><source>mBio</source><volume>11</volume><elocation-id>e02664-20</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02664-20</pub-id><pub-id pub-id-type="pmid">33323507</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Nobori</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Sanaki</surname><given-names>T</given-names></name><name><surname>Toba</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Murai</surname><given-names>A</given-names></name><name><surname>Saito-Tarashima</surname><given-names>N</given-names></name><name><surname>Minakawa</surname><given-names>N</given-names></name><name><surname>Orba</surname><given-names>Y</given-names></name><name><surname>Kariwa</surname><given-names>H</given-names></name><name><surname>Hall</surname><given-names>WW</given-names></name><name><surname>Sawa</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>A</given-names></name><name><surname>Maenaka</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2</article-title><source>iScience</source><volume>24</volume><elocation-id>103120</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.103120</pub-id><pub-id pub-id-type="pmid">34541466</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Sanaki</surname><given-names>T</given-names></name><name><surname>Toba</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Orba</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>WW</given-names></name><name><surname>Maenaka</surname><given-names>K</given-names></name><name><surname>Sawa</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>5376</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-84882-7</pub-id><pub-id pub-id-type="pmid">33686154</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Weringh</surname><given-names>A</given-names></name><name><surname>Ragonnet-Cronin</surname><given-names>M</given-names></name><name><surname>Pranckeviciene</surname><given-names>E</given-names></name><name><surname>Pavon-Eternod</surname><given-names>M</given-names></name><name><surname>Kleiman</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>HIV-1 modulates the tRNA pool to improve translation efficiency</article-title><source>Molecular Biology and Evolution</source><volume>28</volume><fpage>1827</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.1093/molbev/msr005</pub-id><pub-id pub-id-type="pmid">21216840</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadi</surname><given-names>M</given-names></name><name><surname>Anyango</surname><given-names>S</given-names></name><name><surname>Deshpande</surname><given-names>M</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Natassia</surname><given-names>C</given-names></name><name><surname>Yordanova</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Stroe</surname><given-names>O</given-names></name><name><surname>Wood</surname><given-names>G</given-names></name><name><surname>Laydon</surname><given-names>A</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>R</given-names></name><name><surname>Vora</surname><given-names>A</given-names></name><name><surname>Lutfi</surname><given-names>M</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Hobbs</surname><given-names>N</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Kleywegt</surname><given-names>G</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name><name><surname>Velankar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D439</fpage><lpage>D444</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1061</pub-id><pub-id pub-id-type="pmid">34791371</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V’kovski</surname><given-names>P</given-names></name><name><surname>Kratzel</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Stalder</surname><given-names>H</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Coronavirus biology and replication: implications for SARS-CoV-2</article-title><source>Nature Reviews. Microbiology</source><volume>19</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id><pub-id pub-id-type="pmid">33116300</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>J</given-names></name><name><surname>Lampe</surname><given-names>J</given-names></name><name><surname>Müller-Fielitz</surname><given-names>H</given-names></name><name><surname>Schuster</surname><given-names>R</given-names></name><name><surname>Zille</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name><name><surname>Krohn</surname><given-names>M</given-names></name><name><surname>Körbelin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Özorhan</surname><given-names>Ü</given-names></name><name><surname>Neve</surname><given-names>V</given-names></name><name><surname>Wagner</surname><given-names>JUG</given-names></name><name><surname>Bojkova</surname><given-names>D</given-names></name><name><surname>Shumliakivska</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Fähnrich</surname><given-names>A</given-names></name><name><surname>Ott</surname><given-names>F</given-names></name><name><surname>Sencio</surname><given-names>V</given-names></name><name><surname>Robil</surname><given-names>C</given-names></name><name><surname>Pfefferle</surname><given-names>S</given-names></name><name><surname>Sauve</surname><given-names>F</given-names></name><name><surname>Coêlho</surname><given-names>CFF</given-names></name><name><surname>Franz</surname><given-names>J</given-names></name><name><surname>Spiecker</surname><given-names>F</given-names></name><name><surname>Lembrich</surname><given-names>B</given-names></name><name><surname>Binder</surname><given-names>S</given-names></name><name><surname>Feller</surname><given-names>N</given-names></name><name><surname>König</surname><given-names>P</given-names></name><name><surname>Busch</surname><given-names>H</given-names></name><name><surname>Collin</surname><given-names>L</given-names></name><name><surname>Villaseñor</surname><given-names>R</given-names></name><name><surname>Jöhren</surname><given-names>O</given-names></name><name><surname>Altmeppen</surname><given-names>HC</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Püschel</surname><given-names>K</given-names></name><name><surname>Zelic</surname><given-names>M</given-names></name><name><surname>Ofengeim</surname><given-names>D</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name><name><surname>Trottein</surname><given-names>F</given-names></name><name><surname>Nogueiras</surname><given-names>R</given-names></name><name><surname>Hilgenfeld</surname><given-names>R</given-names></name><name><surname>Glatzel</surname><given-names>M</given-names></name><name><surname>Prevot</surname><given-names>V</given-names></name><name><surname>Schwaninger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The SARS-CoV-2 main protease M<sup>pro</sup> causes microvascular brain pathology by cleaving NEMO in brain endothelial cells</article-title><source>Nature Neuroscience</source><volume>24</volume><fpage>1522</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1038/s41593-021-00926-1</pub-id><pub-id pub-id-type="pmid">34675436</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Xun</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>T5 exonuclease-dependent assembly offers a low-cost method for efficient cloning and site-directed mutagenesis</article-title><source>Nucleic Acids Research</source><volume>47</volume><elocation-id>e15</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gky1169</pub-id><pub-id pub-id-type="pmid">30462336</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spatial and temporal roles of SARS-CoV PL(pro) -A snapshot</article-title><source>FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology</source><volume>35</volume><elocation-id>e21197</elocation-id><pub-id pub-id-type="doi">10.1096/fj.202002271</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Miranda-Sanchez</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Kauffman</surname><given-names>KM</given-names></name><name><surname>Acevero</surname><given-names>CM</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name><name><surname>Polz</surname><given-names>MF</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Degradation of host translational machinery drives tRNA acquisition in viruses</article-title><source>Cell Systems</source><volume>12</volume><fpage>771</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2021.05.019</pub-id><pub-id pub-id-type="pmid">34143976</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Lentini</surname><given-names>JM</given-names></name><name><surname>Prevost</surname><given-names>CT</given-names></name><name><surname>Hashem</surname><given-names>MO</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An intellectual disability-associated missense variant in TRMT1 impairs tRNA modification and reconstitution of enzymatic activity</article-title><source>Human Mutation</source><volume>41</volume><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1002/humu.23976</pub-id><pub-id pub-id-type="pmid">31898845</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Methyltransferase-like 3 modulates severe acute respiratory syndrome coronavirus-2 RNA N6-methyladenosine modification and replication</article-title><source>mBio</source><volume>12</volume><elocation-id>e0106721</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.01067-21</pub-id><pub-id pub-id-type="pmid">34225491</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Protease cleavage of RNF20 facilitates coronavirus replication via stabilization of SREBP1</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2107108118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2107108118</pub-id><pub-id pub-id-type="pmid">34452991</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LS</given-names></name><name><surname>Xiong</surname><given-names>QP</given-names></name><name><surname>Peña Perez</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Le</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Harada</surname><given-names>BT</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>ED</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Klungland</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>RJ</given-names></name><name><surname>He</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021c</year><article-title>ALKBH7-mediated demethylation regulates mitochondrial polycistronic RNA processing</article-title><source>Nature Cell Biology</source><volume>23</volume><fpage>684</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/s41556-021-00709-7</pub-id><pub-id pub-id-type="pmid">34253897</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90316.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Yogesh K</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This manuscript provides <bold>important</bold> insights into the degradation of the host tRNA modification enzyme TRMT1 by the SARS-CoV-2 protease Nsp5 (nonstructural protein 5 or MPro). The data <bold>convincingly</bold> support the main conclusions of the paper. These results will be of interest to virologists studying the alterations in tRNA modifications, host methyltransferases, and viral infections.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90316.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Zhang et al. investigate the hypothesis that tRNA methyl transferase 1 (TRMT1) is cleaved by NSP5 (nonstructural protein 5 or MPro), the SARS-CoV-2 main protease, during SARS-CoV-2 infection. They provide solid evidence that TRMT1 is a substrate of Nsp5, revealing an Nsp5 target consensus sequence and evidence of TRMT1 cleavage in cells. Their conclusions are exceptionally strong given the co-submission by D'Oliveira et al showing cleavage of TRMT1 in vitro by Nsp5. The detection of the N-terminal TRMT1 fragment by western blot is not robust; however, the authors provide corroborating assays and detailed densitometry methods, providing confidence to this reviewer that a TRMT1 fragment is produced under some conditions. Separately, the authors convincingly demonstrate widespread downregulation of RNA modifications during CoV-2 infection, including a requirement for TRMT1 in efficient viral replication. This finding is congruent with the authors' previous work defining the impact of TRMT1 and m2,2g on global translation, which is most likely necessary to support infection and virion production. Based on the data provided here, TRMT1 cleavage may be an act by CoV-2 to self-limit replication, as expression of a non-cleavable TRMT1 (versus wild type TRMT1) supports enhanced viral RNA expression at certain MOIs. The authors propose a few fascinating ideas to why this may be so in &quot;Ideas and Speculation.&quot; Theoretically, TRMT1 cleavage should inactivate the modification activity of TRMT1, which the authors thoroughly and elegantly investigate with rigorous biochemical assays. However, only a minority of TRMT1 undergoes cleavage during infection at low MOIs and thus whether TRMT1 cleavage serves an important functional role during CoV-2 replication will be an important topic for future work. The authors fairly assess their work in this regard. In summary, this study demonstrates an important finding that the tRNA modification landscape is altered during CoV-2 infection, and that TRMT1 is an important host factor supporting CoV-2 replication. Their data pushes forward the idea that control of tRNA expression and functionality is an important and understudied area of host-pathogen interaction.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90316.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The manuscript titled 'Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease' from K. Zhang et al., demonstrates that several RNA modifications are downregulated during SARS-CoV-2 infection including the widespread m2,2G methylation, which potentially contributes to changes in host translation. To understand the molecular basis behind this global hypomodification of RNA during infection, the authors focused on the human methyltransferase TRMT1 that catalyzes the m2,2G modification. They reveal that TRMT1 not only interacts with the main SARS-CoV-2 protease (Nsp5) in human cells but is also cleaved by Nsp5. To establish if TRMT1 cleavage by Nsp5 contributes to the reduction in m2,2G levels, the authors show compelling evidence that the TRMT1 fragments are incapable of methylating the RNA substrates due to loss of RNA binding by the catalytic domain. They further determine that expression of full-length TRMT1 is required for optimal SARS-CoV-2 replication in 293T cells. Nevertheless, the cleavage of TRMT1 was dispensable for SARS-CoV-2 replication hinting at the possibility that TRMT1 could be an off-target or fortuitous substrate of Nsp5. Overall, this study will be of interest to virologist and biologists studying the role of RNA modification and RNA modifying enzyme in viral infection.</p><p>Strengths:</p><p>• The authors use state-of-the-art mass spectrometry approach to quantify RNA modifications in human cells infected with SARS-CoV-2.</p><p>• The authors go to great lengths to demonstrate that SARS-CoV-2 main protease, Nsp5, interacts and cleaves TRMT1 in cells and perform important controls when needed. They use a series of overexpression with strategically placed tags on both TRMT1 and Nsp5 to strengthen their observations.</p><p>• The use of an inactive Nsp5 mutant (C145A) strongly supports the claim of the authors that Nsp5 is solely responsible for TRMT1 cleavage in cells.</p><p>• Although the direct cleavage was not experimentally determined, the authors convincingly show that TRMT1 Q530N is not cleaved by Nsp5 suggesting that the predicted cleavage site at this position is most likely the bona fide region processed by Nsp5 in cells.</p><p>• To understand the impact of TRMT1 cleavage on its RNA methylation activity, the authors rigorously test four protein constructs for their capacity not only to bind RNA but also to introduce the m2,2G modification. They demonstrate that the fragments resulting from TRMT1 cleavage are inactive and cannot methylate RNA. They further establish that the C-terminal region of TRMT1 (containing a zinc-finger domain) is the main binding site for RNA.</p><p>• While 293T cells are unlikely an ideal model system to study SARS-CoV-2 infection, the authors use two cell lines and well-designed rescue experiments to uncover that TRMT1 is required for optimal SARS-CoV-2 replication.</p><p>Weaknesses:</p><p>• Immunoblotting is extensively used to probe for TRMT1 degradation by Nsp5 in this study. Regretfully, the polyclonal antibody used by the authors shows strong non-specific binding to other epitopes. This complicates the data interpretation and quantification since the cleaved TRMT1 band migrates very closely to a main non-specific band detected by the antibody (for instance Fig 3A). While this reviewer is concerned about the cross-contamination during quantification of the N-TRMT1, the loss of this faint cleaved band with the TRMT1 Q530N mutant is reassuring. Nevertheless, the poor behavior of this antibody for TRMT1 detection was already reported and the authors should have taken better precautions or designed a different strategy to circumvent the limitation of this antibody by relying on additional tags.</p><p>• While 293T cells are convenient to use, it is not a well-suited model system to study SARS-CoV-2 infection and replication. Therefore, some of the conclusions from this study might not apply to better suited cell systems such as Vero E6 cells or might not be observed in patient infected cells.</p><p>• The reduction of bulk TRMT1 levels is minor during infection of MRC5 cells with SARS-CoV-2 (Fig 1). This does not seem to agree with the more dramatic reduction in m2,2G modification levels. Cellular Localization experiments of TRMT1 would help clarify this. While TRMT1 is found in the cytoplasm and nucleus, it is possible that TRMT1 is more dramatically degraded in the cytoplasm due to easier access by Nsp5.</p><p>• In fig 6, the authors show that TRMT1 is required for optimal SARS-CoV-2 replication. This can be rescued by expressing TRMT1 (fig 7). Nevertheless, it is unknown if the methylation activity of TRMT1 is required. The authors could have expressed an inactive TRMT1 mutant (by disrupting the SAM binding site) to establish if the RNA modification by TRMT1 is important for SARS-CoV-2 replication or if it is the protein backbone that might contribute to other processes.</p><p>• Fig 7, the authors used the Q530N variant to rescue SARS-CoV-2 replication in TRMT1 KO cells. This is an important experiment and unexpectedly reveals that TRMT1 cleavage by Nsp5 is not required for viral replication. To strengthen the claim of the authors that TRMT1 is required to promote viral replication and that its cleavage inhibits RNA methylation, the authors could express the TRMT1 N-terminal construct in the TRMT1 KO cells to assess if viral replication is restored or not to similar levels as WT TRMT1. This will further validate the potential biological importance of TRMT1 cleavage by Nsp5.</p><p>• Fig 7, shows that the TRMT1 Q530N variant rescues SARS-CoV-2 replication to greater levels then WT TRMT1. The authors should discuss this in greater detail and its possible implications with their proposed statement. For instance, are m2,2G levels higher in Q530N compared to WT? Does Q530N co-elute with Nsp5 or is the interaction disrupted in cells?</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90316.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this manuscript, the authors have used biochemical approaches to provide compelling evidence for the cleavage of TRMT1 by SARS-CoV-2 Nsp5 protease.</p><p>This work is of wide interest to biochemists, cell biologists, and structural biologists in the coronavirus (CoV) field. Furthermore, it substantially advances the understanding of how CoV's interact with host factors during infection and modify cellular metabolism.</p><p>Strengths:</p><p>The authors provide multiple lines of biochemical evidence to report a TRMT1-Nsp5 interaction during SARS-CoV-2 infection. They show that the host enzyme TRMT1 is cleaved at a specific site, and that it generates fragments that are incapable of functioning properly. This is an important result because TRMT1 is a critical player in host protein synthesis. This also advances our understanding of virus-host interactions during SARS-CoV-2 infections. Furthermore, this revised submission attempts to address the mechanistic role of TRMT1-Nsp5 interaction.</p><p>Weaknesses:</p><p>The discussion on the enhanced viral infectivity upon expression of the non-cleavable TRMT1 is unclear. As presented, this is a bit contradictory to the suggested function of the TRMT1-Nsp5 interaction in diverting the host tRNA pools towards viral propagation. If the authors' model were correct, then one would expect a non-cleavable TRMT1 to inhibit viral infectivity because the virus would be unable to divert the host tRNA pools towards its propagation. I think this section needs to be written more clearly. But other than this, I have no further questions/suggestions for the authors.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90316.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Kejia</given-names></name><role specific-use="author">Author</role><aff><institution>University of Rochester</institution><addr-line><named-content content-type="city">Rochester, NY</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Eldin</surname><given-names>Patrick</given-names></name><role specific-use="author">Author</role><aff><institution>Institut de Recherche en Infectiologie de Montpellier</institution><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Ciesla</surname><given-names>Jessica H</given-names></name><role specific-use="author">Author</role><aff><institution>University of Rochester Medical Center</institution><addr-line><named-content content-type="city">Rochester, NY</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Briant</surname><given-names>Laurence</given-names></name><role specific-use="author">Author</role><aff><institution>IRIM</institution><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Lentini</surname><given-names>Jenna</given-names></name><role specific-use="author">Author</role><aff><institution>University of Rochester</institution><addr-line><named-content content-type="city">Rochester, NY</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ramos</surname><given-names>Jillian</given-names></name><role specific-use="author">Author</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><addr-line><named-content content-type="city">Denver</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Cobb</surname><given-names>Justin</given-names></name><role specific-use="author">Author</role><aff><institution>University of Rochester</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Munger</surname><given-names>Josh</given-names></name><role specific-use="author">Author</role><aff><institution>University of Rochester</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Dragony</given-names></name><role specific-use="author">Author</role><aff><institution>University of Rochester</institution><addr-line><named-content content-type="city">Rochester, NY</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife assessment</bold></p><p>This manuscript provides important insights into the degradation of a host tRNA modification enzyme TRMT1 by SARS-CoV-2 protease nsp5. The data convincingly support the main conclusions of the paper. These results will be of interest to virologists interested in studying the alterations in tRNA modifications, host methyltransferases, and viral infections.</p><p><bold>Public Reviews:</bold></p></disp-quote><p>Response to Public Reviews</p><p>We appreciate the reviewers’ assessment that our findings are well supported and provide important insight to the field. We also thank the reviewers for their comments and suggestions that have improved the quality of this manuscript. Through the requested edits and experiments, we provide additional results in this revision that further support and extend our original findings.</p><p>We acknowledge the major questions that remain to be addressed, including the biological relevance of TRMT1 cleavage by Nsp5. We note that elucidating the biological role of host protein cleavage by viral proteases has been a long-standing challenge. For example, several endogenous proteins have been identified as cleavage targets of HIV protease, but the functional relevance for many of these cases took decades to resolve or remain unknown to this day. Nonetheless, we have added additional experiments that suggest a possible role for TRMT1 and TRMT1 cleavage in SARS-CoV-2 pathobiology.</p><p>Key additions in the revised manuscript include:</p><p>• Subcellular localization of full-length TRMT1 and TRMT1 fragments (Supplemental Figure 4).</p><p>• Experiments demonstrating that TRMT1 levels are reduced to near background levels in SARS-CoV-2 infected human cells at higher MOI (Figure 6C and D).</p><p>• Results showing that expression of the non-cleavable TRMT1 mutant can promote virion particle infectivity (Figure 8).</p><p>• The addition of an “Ideas and Speculation” subsection that is now being offered to authors by eLife.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Zhang et al. investigate the hypothesis that tRNA methyl transferase 1 (TRMT1) is cleaved by NSP5 (nonstructural protein 5 or MPro), the SARS-CoV-2 main protease, during SARS-CoV-2 infection. They provide solid evidence that TRMT1 is a substrate of Nsp5, revealing an Nsp5 target consensus sequence and evidence of TRMT1 cleavage in cells. Their conclusions are exceptionally strong given the co-submission by D'Oliveira et al showing cleavage of TRMT1 in vitro by Nsp5. Separately, the authors convincingly demonstrate widespread downregulation of RNA modifications during CoV-2 infection, including a requirement for TRMT1 in efficient viral replication. This finding is congruent with the authors' previous work defining the impact of TRMT1 and m2,2g on global translation, which is most likely necessary to support infection and virion production. What still remains unclear is the functional relevance of TRMT1 cleavage by Nsp5 during infection. Based on the data provided here, TRMT1 cleavage may be an act by CoV2 to self-limit replication, as the expression of a non-cleavable TRMT1 (versus wild-type TRMT1) supports enhanced viral RNA expression at certain MOIs. Theoretically, TRMT1 cleavage should inactivate the modification activity of TRMT1, which the authors thoroughly and elegantly investigate with rigorous biochemical assays. However, only a minority of TRMT1 undergoes cleavage during infection in this study and thus whether TRMT1 cleavage serves an important functional role during CoV-2 replication will be an important topic for future work. The authors fairly assess their work in this regard. This study pushes forward the idea that control of tRNA expression and functionality is an important and understudied area of host-pathogen interaction.</p></disp-quote><p>We thank the reviewer for the thoughtful assessment of our study.</p><p>We acknowledge that only a minority of TRMT1 undergoes cleavage during infection at the originally tested MOI. However, the ~40% reduction in TRMT1 levels after infection with SARS-CoV-2 is quite substantial considering that the TRMT1 in the nucleus and mitochondria are likely to be inaccessible to Nsp5. Moreover, we detected a reduction in m2,2G modification in the infected human cells, providing evidence for a functional impact on TRMT1 activity (Figure 1C).</p><p>To further test the effects of SARS-CoV-2 infection on endogenous TRMT1, we infected 293T cells at a higher MOI and measured TRMT1 levels. At MOI=5, we found that SARS-CoV-2 infection led to near complete depletion of TRMT1 in human cells. This result suggests that SARS-CoV-2 infection could have a profound impact on TRMT1 levels during pathogenesis. We have added this new experiment as Figures 6C and D.</p><disp-quote content-type="editor-comment"><p>Weaknesses noted:</p><p>The detection of the N-terminal TRMT1 fragment by western blot is not robust. The polyclonal antibody used to detect TRMT1 in this work cross-reacts with a non-specific protein product. Unfortunately, this obstructs the visualization of the predicted N-terminal TRMT1 fragment. It is unclear how the authors were able to perform densitometry, given the interference of the nonspecific band. Additionally, the replicates in the source data make it clear that the appearance of the N-terminal fragment &quot;wisp&quot; under the non-specific band is not seen in every replicate. Though the disappearance of this wisp with mutant Nsp5 and uncleavable TRMT1 is reassuring, the detection of the N-terminal fragment with the TRMT1 antibody should be assessed critically. Considering this group has strong research interests in TRMT1, I assume that attempts to make other antibodies have proved unfruitful. Additionally, N-terminal tagging of TRMT1 is predicted to disrupt the mitochondrial targeting signal, eliminating the potential for using alternative antibodies to see the N-terminal fragment.</p></disp-quote><p>We agree that the anti-TRMT1 antibody used here is sub-optimal for detection of the N-terminal TRMT1 fragment. However, as noted by the Reviewer, we provided multiple ways of corroborating that the lower-molecular weight band detected in human cells expressing Nsp5 corresponds to the N-terminal TRMT1 fragment. We have shown that the TRMT1 cleavage band is not detectable in human cells expressing GFP or inactive Nsp5. This indicates that the lower molecular weight TRMT1 band only arises when active Nsp5 protease is expressed. Moreover, the TRMT1 cleavage band is not detectable in TRMT1-KO cell lines, demonstrating that the band arises from TRMT1 cleavage rather than a non-specific protein. We have also detected the C-terminal fragment if TRMT1 is over-expressed with Nsp5. In addition, we have shown that the mutation of the predicted Nsp5 cleavage site in TRMT1 abolishes the appearance of the N- and Cterminal cleavage fragments.</p><p>Despite the drawbacks of this antibody, we identified gel running conditions that resolves the non-specific band from the N-terminal TRMT1 cleavage fragment. Thus, for quantification, we measured the total signal of both the cleavage band and the nonspecific band in all lanes (Figure 3). After normalization to actin, the total signal from the cleavage band and the non-specific band in the control lane from cells expressing GFP was subtracted from the lanes with cells expressing Nsp5 to calculate the signal arising from the cleavage band. We have updated our Materials and Methods to provide details on how we quantified the TRMT1 cleavage band.</p><p>While we did test other antibodies against TRMT1, none of them were sensitive enough to detect TRMT1 cleavage fragments at endogenous levels. For example, we included results with an antibody targeting the C-terminus of TRMT1 that could not detect TRMT1 cleavage products at endogenous levels (Supplemental Figure 3). However, the antibody could detect the C-terminal TRMT1 fragments if TRMT1 was overexpressed with Nsp5 (Supplemental Figure 3).</p><disp-quote content-type="editor-comment"><p>These technical issues reiterate the fact that the functional significance of TRMT1 cleavage during CoV-2 infection remains unclear. However, this study demonstrates an important finding that the tRNA modification landscape is altered during CoV-2 infection and that TRMT1 is an important host factor supporting CoV-2 replication.</p></disp-quote><p>We agree that the functional relevance of TRMT1 cleavage by Nsp5 remains an open question. Thus, we have added an experiment to test the functional impact of TRMT1 on virion particle production and infectivity (Figure 8). We find that TRMT1 expression is required for optimal virus production, consistent with our observation that TRMT1deficient cells exhibit reduced viral RNA replication. In addition, we find that expression of the non-cleavable TRMT1 mutant can promote virion particle infectivity (Figure 8, TRMT1-Q530N). These results are consistent with the Reviewer’s conclusion that “TRMT1 cleavage may be an act by CoV-2 to self-limit replication, as the expression of a non-cleavable TRMT1 (versus wild-type TRMT1) supports enhanced viral RNA expression at certain MOIs”. We discuss the potential implications of this result and their functional relevance in the “Ideas and Speculation” subsection.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>The manuscript titled 'Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease' from K. Zhang et al. demonstrates that several RNA modifications are downregulated during SARS-CoV-2 infection including the widespread m2,2G methylation, which potentially contributes to changes in host translation. To understand the molecular basis behind this global hypomodification of RNA during infection, the authors focused on the human methyltransferase TRMT1 that catalyzes the m2,2G modification. They reveal that TRMT1 not only interacts with the main SARS-CoV-2 protease (Nsp5) in human cells but is also cleaved by Nsp5. To establish if TRMT1 cleavage by Nsp5 contributes to the reduction in m2,2G levels, the authors show compelling evidence that the TRMT1 fragments are incapable of methylating the RNA substrates due to loss of RNA binding by the catalytic domain. They further determine that expression of full-length TRMT1 is required for optimal SARS-CoV-2 replication in 293T cells. Nevertheless, the cleavage of TRMT1 was dispensable for SARS-CoV-2 replication hinting at the possibility that TRMT1 could be an off-target or fortuitous substrate of Nsp5. Overall, this study will be of interest to virologists and biologists studying the role of RNA modification and RNA modifying enzymes in viral infection.</p></disp-quote><p>We thank the reviewer for the thoughtful assessment of our study.</p><p>We agree with the possibility that TRMT1 could be a fortuitous substrate of Nsp5 due to the coincidental presence of a Nsp5 cleavage site in TRMT1. As considered in our Discussion section, TRMT1 cleavage could be a collateral effect of SARS-CoV-2 infection. While TRMT1 could be an off-target substrate during viral infection, the subsequent effect on tRNA modification levels could have physiological consequences on downstream processes that affect cellular health. This information could still be useful for understanding the pathophysiological consequences of SARS-CoV-2 infection in tissues.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><list list-type="bullet"><list-item><p>The authors use a state-of-the-art mass spectrometry approach to quantify RNA modifications in human cells infected with SARS-CoV-2.</p></list-item></list><list list-type="bullet"><list-item><p>The authors go to great length to demonstrate that SARS-CoV-2 main protease, Nsp5, interacts, and cleaves TRMT1 in cells and perform important controls when needed. They use a series of overexpression with strategically placed tags on both TRMT1 and Nsp5 to strengthen their observations.</p></list-item></list><list list-type="bullet"><list-item><p>The use of an inactive Nsp5 mutant (C145A) strongly supports the claim of the authors that Nsp5 is solely responsible for TRMT1 cleavage in cells.</p></list-item></list><list list-type="bullet"><list-item><p>Although the direct cleavage was not experimentally determined, the authors convincingly show that TRMT1 Q530N is not cleaved by Nsp5 suggesting that the predicted cleavage site at this position is most likely the bona fide region processed by Nsp5 in cells.</p></list-item></list><list list-type="bullet"><list-item><p>To understand the impact of TRMT1 cleavage on its RNA methylation activity, the authors rigorously test four protein constructs for their capacity not only to bind RNA but also to introduce the m2,2G modification. They demonstrate that the fragments resulting from TRMT1 cleavage are inactive and cannot methylate RNA. They further establish that the C-terminal region of TRMT1 (containing a zinc-finger domain) is the main binding site for RNA.</p></list-item></list><list list-type="bullet"><list-item><p>While 293T cells are unlikely an ideal model system to study SARS-CoV-2 infection, the authors use two cell lines and well-designed rescue experiments to uncover that TRMT1 is required for optimal SARS-CoV-2 replication.</p></list-item></list><p>Weaknesses:</p><list list-type="bullet"><list-item><p>Immunoblo0ng is extensively used to probe for TRMT1 degradation by Nsp5 in this study. Regretfully, the polyclonal antibody used by the authors shows strong non-specific binding to other epitopes. This complicates the data interpretation and quantification since the cleaved TRMT1 band migrates very closely to a main non-specific band detected by the antibody (for instance Fig 3A). While this reviewer is concerned about the cross-contamination during quantification of the N-TRMT1, the loss of this faint cleaved band with the TRMT1 Q530N mutant is reassuring. Nevertheless, the poor behavior of this antibody for TRMT1 detection was already reported and the authors should have taken better precautions or designed a different strategy to circumvent the limitation of this antibody by relying on additional tags.</p></list-item></list></disp-quote><p>We acknowledge the sub-optimal performance of the commercial anti-TRMT1 antibody used in our study. Nevertheless, we have provided multiple lines of evidence indicating that the lower molecular weight band detected using this antibody corresponds to the N-terminal TRMT1 fragment. As noted by the reviewer, we have shown that the lower molecular weight band disappears using the TRMT1-Q530N non-cleavable mutant. The lower molecular weight signal is also absent in TRMT1-KO cell lines expressing Nsp5. Moreover, we have shown that the TRMT1 cleavage band is undetectable in human cells expressing GFP or inactive Nsp5. We have also detected the C-terminal fragment when TRMT1 is over-expressed with Nsp5.</p><p>As discussed in the response to Reviewer 1, we did consider alternative approaches for detecting the N-terminal fragment. We thought about tagging TRMT1 at the N-terminus so that we could detect the cleavage band using a different antibody. However, as noted by Reviewer 1, the tagging of TRMT1 at the N-terminus is likely to disrupt the mitochondrial targeting signal and alter the localization of TRMT1. In addition, we spent considerable time and effort testing alternative antibodies against TRMT1. However, none of them were effective at detecting the N- or C-terminal TRMT1 fragments. For example, we included results with a different antibody targeting the C-terminus of TRMT1 that could not detect TRMT1 cleavage products at endogenous levels but could detect them when TRMT1 was overexpressed with Nsp5 (Supplemental Figure 3).</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>While 293T cells are convenient to use, it is not a well-suited model system to study SARS-CoV2 infection and replication. Therefore, some of the conclusions from this study might not apply to better-suited cell systems such as Vero E6 cells or might not be observed in patient-infected cells.</p></list-item></list></disp-quote><p>We acknowledge the potential caveats associated with using 293T human embryonic cells as a system for testing SARS-CoV2 replication. However, we note that 293T cells have been used as a physiological model for discovering and characterizing key aspects of SARS-CoV-2 biology, including viral replication. For example, SARS-CoV-2 has been shown to exhibit significant replication and virion production in 293T cells expressing ACE2 that can be inhibited by known SARS-CoV-2 antiviral compounds:</p><p>• <ext-link ext-link-type="uri" xlink:href="https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)300045/fulltext">https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)300045/fulltext</ext-link></p><p>• <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444585/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444585/</ext-link></p><p>• <ext-link ext-link-type="uri" xlink:href="https://www.science.org/doi/10.1126/sciadv.add3867">https://www.science.org/doi/10.1126/sciadv.add3867</ext-link></p><p>• <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/doi/full/10.1073/pnas.2025866118">https://www.pnas.org/doi/full/10.1073/pnas.2025866118</ext-link></p><p>293T cells have also been demonstrated to exhibit cytopathic effects upon SARS-CoV-2 infection that are dependent upon the ACE2 receptor and mirror that of infected lung cells in culture and in patient tissues:</p><p>• <ext-link ext-link-type="uri" xlink:href="https://www.embopress.org/doi/full/10.15252/embj.2020106267">https://www.embopress.org/doi/full/10.15252/embj.2020106267</ext-link></p><p>• <ext-link ext-link-type="uri" xlink:href="https://journals.asm.org/doi/full/10.1128/jvi.00002-22">https://journals.asm.org/doi/full/10.1128/jvi.00002-22</ext-link></p><p>• <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009715">https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009715</ext-link></p><p>• <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41559-021-01407-1">https://www.nature.com/articles/s41559-021-01407-1</ext-link></p><p>In addition to 293T cells, we have demonstrated that infection of MRC5 human pulmonary fibroblast cells with SARS-CoV-2 results in a decrease in TRMT1 levels and m2,2G modification (Figure 1). The reduction in TRMT1 levels in MRC5 cells after SARS-CoV-2 infection is similar to that observed in 293T cells.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>The reduction of bulk TRMT1 levels is minor during infection of MRC5 cells with SARS-CoV-2 (Fig 1). This does not seem to agree with the more dramatic reduction in m2,2G modification levels. Cellular Localization experiments of TRMT1 would help clarify this. While TRMT1 is found in the cytoplasm and nucleus, it is possible that TRMT1 is more dramatically degraded in the cytoplasm due to easier access by Nsp5.</p></list-item></list></disp-quote><p>We agree that the processing of newly synthesized TRMT1 in the cytoplasm is likely to be the main cause for the reduction of TRMT1 levels in the infected MRC5 cells. Thus, we followed the Reviewer’s suggestion to conduct cellular localization experiments of TRMT1 (Supplemental Figure 4). Through these experiments, we show that full-length TRMT1 exhibits localization to the cytoplasm, mitochondria, and nucleus, consistent with prior findings from our group and others. This result supports the conclusion that cytoplasmic TRMT1 is the likely target of Nsp5 cleavage while TRMT1 in the nucleus and mitochondria are inaccessible to Nsp5. We also note that the decrease in cytoplasmic TRMT1 could account for the reduction in m2,2G modifications if the cytoplasmic pool of TRMT1 is responsible for modifying any exported tRNAs that were not modified in the nucleus.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>In Fig 6, the authors show that TRMT1 is required for optimal SARS-CoV-2 replication. This can be rescued by expressing TRMT1 (Fig 7). Nevertheless, it is unknown if the methylation activity of TRMT1 is required. The authors could have expressed an inactive TRMT1 mutant (by disrupting the SAM binding site) to establish if the RNA modification by TRMT1 is important for SARS-CoV-2 replication or if it is the protein backbone that might contribute to other processes.</p></list-item></list></disp-quote><p>We agree that it would be interesting to test if the methylation activity of TRMT1 is important for optimal SARS-CoV-2 replication. However, the present study focuses on the cleavage of TRMT1 by Nsp5 and the biological effects of this cleavage. Thus, we feel that generating another human cell line lies outside the scope of this paper and would be an excellent idea for future studies. We thank the reviewer for the proposed experiment.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Fig 7, the authors used the Q530N variant to rescue SARS-CoV-2 replication in TRMT1 KO cells. This is an important experiment and unexpectedly reveals that TRMT1 cleavage by Nsp5 is not required for viral replication. To strengthen the claim of the authors that TRMT1 is required to promote viral replication and that its cleavage inhibits RNA methylation, the authors could express the TRMT1 N-terminal construct in the TRMT1 KO cells to assess if viral replication is restored or not to similar levels as WT TRMT1. This will further validate the potential biological importance of TRMT1 cleavage by Nsp5.</p></list-item></list></disp-quote><p>Indeed, we did not expect to find that human cells expressing the TRMT1-Q530N variant exhibit higher levels of viral replication. This suggests that cleavage of TRMT1 is inhibitory for viral replication. To provide further support for this observation, we analyzed the viral titer and infectivity of supernatants derived from human cells expressing wildtype TRMT1 or TRMT1-Q530N. Consistent with our finding that TRMT1-Q530N cells contain more viral RNA, the media supernatants from TRMT1Q530N expressing cells exhibit higher viral titer and infectivity compared to supernatants from TRMT1-KO cells expressing wildtype TRMT1. These results provide additional evidence that TRMT1 is required to promote viral replication. Moreover, these findings suggest that TRMT1 cleavage and reduced protein synthesis could selflimit viral replication. The additional results have been added as Figure 8.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Fig 7 shows that the TRMT1 Q530N variant rescues SARS-CoV-2 replication to greater levels then WT TRMT1. The authors should discuss this in greater detail and its possible implications with their proposed statement. For instance, are m2,2G levels higher in Q530N compared to WT? Does Q530N co-elute with Nsp5 or is the interaction disrupted in cells?</p></list-item></list></disp-quote><p>These are excellent points brought up by the Reviewer. As noted above, we have added an additional experiment that tests the functional relevance of TRMT1 expression and cleavage on virion production and infectivity (Figure 8). Moreover, we have followed the Reviewer’s suggestion and discussed the potential implications of these findings in the “Ideas and Speculation” subsection.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>In this manuscript, the authors have used biochemical approaches to provide compelling evidence for the cleavage of TRMT1 by SARS-CoV-2 Nsp5 protease. This work is of wide interest to biochemists, cell biologists, and structural biologists in the coronavirus (CoV) field. Furthermore, it substantially advances the understanding of how CoV's interact with host factors during infection and modify cellular metabolism.</p></disp-quote><p>We thank the reviewer for the thoughtful assessment of our study.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>The authors provide multiple lines of biochemical evidence to report a TRMT1-Nsp5 interaction during SARS-CoV-2 infection. They show that the host enzyme TRMT1 is cleaved at a specific site and that it generates fragments that are incapable of functioning properly. This is an important result because TRMT1 is a critical player in host protein synthesis. This also advances our understanding of virus-host interactions during SARS-CoV-2 infections.</p><p>Weaknesses:</p><p>The major weakness is the lack of mechanistic insights into TRMT1-Nsp5 interactions. The authors have provided commendable biochemical data on proving the TRMT1-Nsp5 interaction but without clear mechanistic insights into when this interaction takes place in the context of SARS-CoV-2 propagation, what are the functional consequences of this interaction on host biology, and does this somehow benefit the infecting virus? I feel that the authors played it a bit safe despite having access to several reagents and an extremely promising research direction.</p></disp-quote><p>We agree that our findings have prompted questions on the mechanistic and functional relevance of TRMT1 cleavage by Nsp5. To begin addressing the latter point, we have included a new experiment testing the impact of TRMT1 expression and cleavage on SARS-CoV-2 virus production and infectivity (Figure 8). We find that TRMT1-deficient cells infected with SARS-CoV-2 exhibit less virion production and the viruses produced are less infectious. Intriguingly, we find that expression of the non-cleavable TRMT1-Q530N variant in TRMT1-KO cells promotes an increase of viral titer as well as infectivity compared to expression of wildtype TRMT1. These results provide evidence for an unexpected role for TRMT1 expression in virus production and the generation of optimally infectious SARS-CoV-2 particles. We discuss the potential implications of this finding in the “Ideas and Speculation” subsection.</p><p>We agree that understanding the timing and effects of Nsp5-TRMT1 interaction will be an important area of investigation moving forward. We would like to include additional time points beyond 24- and 48-hours post-infection. However, we have found that the MRC5-ACE2 cells exhibited increased levels of cell death at 72 and 96-hours postinfection that could confound results (Raymonda et al 2022). Moreover, we would like to know how the reduction in m2,2G modifications affects host tRNA biology and translation. However, these experiments involve large-scale methods such as tRNA sequencing and ribosome profiling which are outside the scope of our current studies and will be the subject of future efforts.</p><p>We acknowledge the Reviewer’s assessment that we “played it a bit safe” in discussing the functional consequences of Nsp5-TRMT1 interaction. We aimed for a circumspect interpretation of our results and their biological implications, but might have been too cautious in our conclusions. Thus, we have added an “Ideas and Speculation” subsection that discusses possible reasons for how TRMT1 cleavage and interaction with Nsp5 could benefit the virus. We thank the Reviewer for pointing out this issue in our initial manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Having reviewed an earlier version of this manuscript, I appreciated the recent progress made by the authors. I felt the entire body of work is quite solid and the interpretations are clear and not overstated. One piece of data I thought deserved a sentence or two of discussion was the complementation assay with Q530N TRMT1. This experiment suggests the possibility that cleavage of TRMT1 by Nsp5 may be an act to self-limit replication, although this result could also be due to the elevated levels of Q530N TRMT1 expression compared to WT. I still think it is worthy of discussion. Another thing I would recommend is to include the length of infection by SARS-CoV-2 in the figure legends.</p></disp-quote><p>We thank the reviewer for their positive response and constructive comments.</p><p>We have followed the Reviewer’s suggestion to further discuss how cleavage of TRMT1 may act to self-limit replication in the “Ideas and Speculation” subsection. We have also included the length of infection by SARS-CoV-2 in the figure legends.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors)</bold>:</p><p>In addition to the comments mentioned in the public review, this reviewer encourages the authors to address the following points:</p><list list-type="bullet"><list-item><p>Please clarify the rationale behind choosing 24 and 48 hours post-infection as time points for the analyses (Fig 1). One would expect even lower levels of TRMT1 and RNA modification after 72 and 96 hours post-infection.</p></list-item></list></disp-quote><p>We chose the 24 and 48-hour time points since we have shown that MRC5 cells exhibit elevated accumulation of viral RNA at these time points (Raymonda et al 2022). However, at 72 and 96-hours post-infection, we have found that the MRC5-ACE2 cells exhibited cytopathic effects indicative of cell death that could confound results. We have included the rationale for these time points in our revised manuscript.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>In Supplementary Figure 3, please add in the legend the meaning of the asterisk symbol.</p></list-item></list></disp-quote><p>The asterisks denote non-specific bands that are still detectable in the TRMT1-KO cell line. We have updated the Figure Legend and thank the Reviewer for catching this omission.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>In Supplementary Figure 3B, there is an intermediate band in lane 3 with C145A when using the antibody 609-659. The authors should clarify what that band is.</p></list-item></list></disp-quote><p>The intermediate band in lane 3 (and in lane 6) of Supplemental Figure 3B represents non-specific detection of the Nsp5-C145A variant that exhibits extremely high levels of expression since it cannot self-cleave. We have clarified the identity of the band in the figure legend.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>I have only minor comments:</p><p>Although the authors have done a commendable job of providing compelling biochemical evidence of TRMT1 cleavage by Nsp5, it is not clear how this enhances viral infection. The discussion presents the experimental findings and prior publications as a series of correlated observations without clearly specifying the mechanistic benefits of TRMT1 hijacking towards CoV propagation, or even proposing a mechanistic hypothesis to this end.</p></disp-quote><p>We agree with the Reviewer that providing a mechanistic hypothesis on how TRMT1 cleavage impacts virus biology will help inform future studies. We have followed the Reviewer’s suggestion and discuss potential mechanisms in the “Ideas and Speculation” subsection.</p><disp-quote content-type="editor-comment"><p>How do these experiments inform us about the cell biology of SARS-CoV- infections? Does Nsp5-mediated degradation start early in infection? Is the loss of TRMT1 sustained over the course of the infection? Do Nsp5 concentrations or relative amounts correlate with TRMT1 loss during this period? For instance, is there only a modest increase in Nsp5 levels from 24h to 48h? I would suggest adding a few more data points than just 24h and 48h in the cell culture experiments. As the manuscript stands right now, it will be a bit difficult for readers to appreciate the relevance of this study in its present form.</p></disp-quote><p>These are excellent questions raised by the Reviewer. The temporal effects of SARSCoV-2 infection on TRMT1 levels will be an important area to dissect moving forward.</p><p>As mentioned above, we would like to include additional time points beyond 24- and 48-hours post-infection. However, at 72 and 96-hours post-infection, we have found that the MRC5-ACE2 cells exhibited increased levels of cell death that could confound results.</p><p>However, we do observe a correlation between the level of infection and the amount of TRMT1 depletion. In our newly added Figure 6C and 6D, we show that increasing the MOI leads to a concomitant increase in N-protein production that correlates with the amount of TRMT1 depletion. Moreover, we have added additional experiments to explore the biological relevance of our findings in terms of virion particle production and infectivity. We thank the reviewer for these insightful questions that have improved our manuscript and provide a foundation for future studies.</p><disp-quote content-type="editor-comment"><p>Related to this previous comment: how do the authors rationalize their inference that TRMT1 is essential for SARS-CoV-2 infection, yet it is cleaved during the infection? What seems to be the advantage of this seemingly contradictory but possibly quite intriguing inference?</p></disp-quote><p>We acknowledge the paradox that TRMT1 seems to be essential for SARS-CoV-2 replication but is cleaved during the infection. We propose several hypotheses to explain these findings:</p><p>Hypothesis 1: TRMT1 could be a bystander target. The loss of TRMT1 expression leads to a decrease in modifications that impacts translation. This decrease in translation capacity of the infected cells would lead to decreased production of viral proteins and reduced viral replication. This could explain why TRMT1-deficient cells exhibit less virus production. This could also account for why the TRMT1-Q530N mutant might produce more virus. In this case, the cleavage of TRMT1 and biological effects on viral replication and virion production are coincidental. However, even if TRMT1 cleavage and inactivation does not impact viral replication or production, it would still be important to know the cellular impacts that contribute to disease pathogenesis.</p><p>Hypothesis 2: The slight diminishment of viral replication due to host translation inhibition could outweigh the benefits of shutting down host responses dependent upon protein synthesis. The decrease in TRMT1-catalyzed tRNA modification caused by Nsp5 cleavage could severely inhibit host translation while viral translation can still be maintained through a tRNA pool optimized for viral translation, albeit at a slightly lower rate than if TRMT1 is not cleaved.</p><p>Hypotheses 3: The Nsp5-TRMT1 interaction could allow the virus to bind tRNAs that are packaged in viral particles as suggested previously (Pena et al., 2022). The finding that expression of the non-cleavable TRMT1-Q530N variant enhances viral replication and infectivity supports the hypothesis that TRMT1 could facilitate tRNA uptake into viral particles. The packaging of specific tRNAs in viral particles could enhance viral translation in the subsequent round of infection, thereby enhancing infectivity and perhaps facilitating the species jump of SARS-CoV-2 towards hosts with incompatible codon bias.</p><p>We have included these hypotheses in the new “Ideas and Speculation” subsection.</p></body></sub-article></article>